chr7:55086710:> Detail (hg19) (EGFR)
Information
Genome
Assembly | Position |
---|---|
hg19 | chr7:55,086,710-55,279,321 |
hg38 | chr7:55,019,017-55,211,628 |
HGVS
Type | Transcript | Protein |
---|---|---|
Summary
MGeND
Clinical significance | |
Variant entry | |
GWAS entry | |
Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
Clinical Significance | |
Review star | [No Data.] |
Show details |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
---|---|---|---|---|---|---|---|---|---|
lung non-small cell carcinoma | Gefitinib | C |
![]() |
![]() |
Sensitivity/Response | Somatic | 4 | 24755888 | Detail |
lung adenocarcinoma | Erlotinib | B |
![]() |
![]() |
Sensitivity/Response | Somatic | 4 | 22285168 | Detail |
lung non-small cell carcinoma | Erlotinib | C |
![]() |
![]() |
Sensitivity/Response | Somatic | 21531810 | Detail | |
lung non-small cell carcinoma | Erlotinib,Gefitinib | B |
![]() |
![]() |
Sensitivity/Response | Somatic | 4 | 21531810 | Detail |
lung non-small cell carcinoma | Erlotinib,Gefitinib | B |
![]() |
![]() |
Sensitivity/Response | Somatic | 4 | 21531810 | Detail |
lung non-small cell carcinoma | Erlotinib,Gefitinib | B |
![]() |
![]() |
Sensitivity/Response | Somatic | 2 | 21531810 | Detail |
lung adenocarcinoma | Erlotinib | C |
![]() |
![]() |
Resistance | Somatic | 24353160 | Detail | |
lung non-small cell carcinoma | Erlotinib | C |
![]() |
![]() |
Resistance | Somatic | 24353160 | Detail | |
lung adenocarcinoma | Erlotinib | C |
![]() |
![]() |
Resistance | Somatic | 24353160 | Detail |
DisGeNET
Score | Disease name | Description | Source | Pubmed | Links |
---|---|---|---|---|---|
0.277 | squamous cell carcinoma | Detection of mutation-specific epidermal growth factor receptor (E746-A750del) a... | BeFree,CTD_human,GAD,LHGDN | 24818747 | Detail |
0.277 | squamous cell carcinoma | Lack of mutations in protein tyrosine kinase domain coding exons 19 and 21 of th... | BeFree,CTD_human,GAD,LHGDN | 24969895 | Detail |
0.277 | squamous cell carcinoma | Over-expression of epidermal growth factor receptor (EGFR) has been identified a... | BeFree,CTD_human,GAD,LHGDN | 25081654 | Detail |
0.277 | squamous cell carcinoma | Our results suggest that EGFR expression in squamous cell carcinoma is different... | BeFree,CTD_human,GAD,LHGDN | 25279714 | Detail |
0.277 | squamous cell carcinoma | Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carc... | BeFree,CTD_human,GAD,LHGDN | 25510664 | Detail |
0.277 | squamous cell carcinoma | Our data show that the overall frequency of EGFR gene mutations in lung adenocar... | BeFree,CTD_human,GAD,LHGDN | 25534657 | Detail |
0.277 | squamous cell carcinoma | The occurrence of EGFR mutations in pulmonary SQCC might be overestimated. | BeFree,CTD_human,GAD,LHGDN | 25684486 | Detail |
0.277 | squamous cell carcinoma | Shikonin causes cell-cycle arrest and induces apoptosis by regulating the EGFR-N... | BeFree,CTD_human,GAD,LHGDN | 25720435 | Detail |
0.277 | squamous cell carcinoma | Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-ind... | BeFree,CTD_human,GAD,LHGDN | 25723392 | Detail |
0.277 | squamous cell carcinoma | High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas A... | BeFree,CTD_human,GAD,LHGDN | 25931286 | Detail |
0.277 | squamous cell carcinoma | This study details the empirical basis for a feasible clinical solution for squa... | BeFree,CTD_human,GAD,LHGDN | 26216950 | Detail |
0.004 | Carcinoma, Transitional Cell | NA | BeFree | Detail | |
<0.001 | carcinosarcoma | NA | BeFree | Detail | |
0.203 | Cardiomyopathy, Dilated | NA | BeFree,CTD_human,GAD,RGD | Detail | |
<0.001 | celiac disease | NA | BeFree | Detail | |
0.006 | Malignant tumor of cervix | Studies in cervical cancer indicate that E5 increases epidermal growth factor re... | BeFree | 25027574 | Detail |
0.006 | Malignant tumor of cervix | FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and rep... | BeFree | 25151576 | Detail |
<0.001 | Cervical dysplasia | NA | BeFree | Detail | |
0.130 | Uterine Cervical Neoplasm | NA | CTD_human,GAD,LHGDN | Detail | |
<0.001 | Developmental Disabilities | NA | BeFree | Detail | |
<0.001 | cholera | NA | BeFree | Detail | |
<0.001 | cholesteatoma | NA | BeFree | Detail | |
<0.001 | chondrosarcoma | NA | BeFree | Detail | |
0.002 | chordoma | We find that miR-34a inversely correlates with MET expression and miR-608 invers... | BeFree | 24621885 | Detail |
0.001 | choriocarcinoma | NA | BeFree | Detail | |
0.005 | Chromosome Aberrations | NA | GAD | Detail | |
<0.001 | Congenital chromosomal disease | NA | BeFree | Detail | |
0.002 | Chromosome Deletion | NA | GAD | Detail | |
<0.001 | colitis | NA | BeFree | Detail | |
<0.001 | ulcerative colitis | NA | BeFree | Detail | |
0.140 | Colonic Neoplasms | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
0.170 | Colorectal Neoplasms | Three different macroscopic subtypes of colorectal neoplasms display distinct ca... | BeFree,CTD_human,GAD,LHGDN | 25551625 | Detail |
0.170 | Colorectal Neoplasms | We exploited circulating tumor DNA (ctDNA) to genotype colorectal tumors and tra... | BeFree,CTD_human,GAD,LHGDN | 26030179 | Detail |
<0.001 | common cold | We validated COLD-ddPCR on multiple mutations in TP53 and in EGFR using serial m... | BeFree | 25772705 | Detail |
<0.001 | Coughing | NA | BeFree | Detail | |
<0.001 | craniopharyngioma | NA | BeFree | Detail | |
<0.001 | craniosynostosis | NA | BeFree | Detail | |
0.001 | adenoid cystic carcinoma | NA | BeFree | Detail | |
0.004 | Phyllodes Tumor | Taken together, this study defines the genomic landscape underlying phyllodes tu... | BeFree,LHGDN | 25593300 | Detail |
0.003 | Cytomegalovirus Infections | NA | LHGDN | Detail | |
0.003 | Cessation of life | NA | LHGDN | Detail | |
<0.001 | Demyelinating Diseases | NA | BeFree | Detail | |
<0.001 | Mental Depression | NA | BeFree | Detail | |
<0.001 | depressive disorder | NA | BeFree | Detail | |
<0.001 | dermatitis | NA | BeFree | Detail | |
0.002 | Drug Eruptions | NA | GAD | Detail | |
<0.001 | Dermatitis, Atopic | Staphylococcus aureus skin colonization is universal in atopic dermatitis and co... | BeFree | 25902485 | Detail |
<0.001 | dermoid cyst | NA | BeFree | Detail | |
<0.001 | Diabetes | NA | BeFree | Detail | |
0.001 | diabetes mellitus | The 13 patients with DM were more likely to express IGF-1R (p=0.001) and had sho... | BeFree | 25617986 | Detail |
0.080 | Diabetes Mellitus, Experimental | NA | RGD | Detail | |
0.080 | Diabetes Mellitus, Insulin-Dependent | NA | RGD | Detail | |
0.120 | Diabetes Mellitus, Non-Insulin-Dependent | NA | BeFree,CTD_human | Detail | |
<0.001 | Diabetic Nephropathy | NA | BeFree | Detail | |
0.007 | diarrhea | In addition, EGFR wild type receptor inhibition inherent with these agents can l... | BeFree,GAD | 25271963 | Detail |
<0.001 | diphtheria | NA | BeFree | Detail | |
<0.001 | Dry Eye Syndromes | IL-6, IL-9, CCL24, CCL18, IL-10, IFN-γ, and CCL2 were highly increased (>6-fold)... | BeFree | 26200497 | Detail |
<0.001 | Dupuytren Contracture | NA | BeFree | Detail | |
<0.001 | Dyspnea | NA | BeFree | Detail | |
<0.001 | Eczema | Staphylococcus aureus skin colonization is universal in atopic dermatitis and co... | BeFree | 25902485 | Detail |
<0.001 | subacute bacterial endocarditis | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have s... | BeFree | 25242669 | Detail |
<0.001 | Endocrine Gland Neoplasms | NA | BeFree | Detail | |
<0.001 | Yolk Sac Tumor | NA | BeFree | Detail | |
0.005 | Endometrial Neoplasms | NA | GAD,LHGDN | Detail | |
0.127 | endometriosis | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
0.004 | Ependymoma | NA | BeFree,LHGDN | Detail | |
<0.001 | Epilepsy, Temporal Lobe | NA | BeFree | Detail | |
<0.001 | Erythroplasia | NA | BeFree | Detail | |
0.140 | Esophageal Neoplasms | We show for the first time a significant treatment response to the EGFR tyrosine... | BeFree,CTD_human,GAD,LHGDN | 25070024 | Detail |
0.080 | peptic esophagitis | NA | RGD | Detail | |
0.011 | Exanthema | NA | BeFree,GAD | Detail | |
<0.001 | Muscular fasciculation | NA | BeFree | Detail | |
<0.001 | Fatty Liver | NA | BeFree | Detail | |
<0.001 | breast fibrocystic disease | NA | BeFree | Detail | |
0.003 | Fibrosis | NA | LHGDN | Detail | |
<0.001 | pathologic fistula | NA | BeFree | Detail | |
<0.001 | Flatulence | NA | BeFree | Detail | |
0.120 | gallbladder neoplasm | NA | CTD_human | Detail | |
<0.001 | gastrinoma | NA | BeFree | Detail | |
<0.001 | gastritis | NA | BeFree | Detail | |
<0.001 | Gastritis, Atrophic | NA | BeFree | Detail | |
<0.001 | gastroesophageal reflux disease | NA | BeFree | Detail | |
<0.001 | Gastrointestinal Neoplasms | NA | BeFree | Detail | |
0.003 | Gliosis | NA | LHGDN | Detail | |
<0.001 | goiter | NA | BeFree | Detail | |
<0.001 | Graft-vs-Host Disease | IL-6, IL-9, CCL24, CCL18, IL-10, IFN-γ, and CCL2 were highly increased (>6-fold)... | BeFree | 26200497 | Detail |
<0.001 | granulosa cell tumor | Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 r... | BeFree | 24206174 | Detail |
<0.001 | Hamartoma | NA | BeFree | Detail | |
0.003 | Hay fever | NA | BeFree,LHGDN | Detail | |
0.130 | Head and Neck Neoplasms | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
<0.001 | Heart Diseases | NA | BeFree | Detail | |
<0.001 | Heart failure | NA | BeFree | Detail | |
<0.001 | congestive heart failure | NA | BeFree | Detail | |
<0.001 | Helminthiasis | NA | BeFree | Detail | |
<0.001 | Hematological Disease | NA | BeFree | Detail | |
<0.001 | hepatitis B | NA | BeFree | Detail | |
0.006 | hepatitis C | Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits he... | BeFree,GAD,LHGDN | 25757571 | Detail |
0.006 | hepatitis C | Hepatitis C virus NS5A protein blocks epidermal growth factor receptor degradati... | BeFree,GAD,LHGDN | 25872741 | Detail |
0.006 | hepatitis C | Impact of epidermal growth factor receptor and transforming growth factor-α on h... | BeFree,GAD,LHGDN | 26279457 | Detail |
0.001 | Herpes Simplex Infections | To address the concern that this safety feature may reduce oncolytic activity, w... | BeFree | 25200130 | Detail |
0.001 | HIV Infections | A multi-institutional study of clinicopathological features and molecular epidem... | BeFree | 25800620 | Detail |
<0.001 | Hydatidiform mole | NA | BeFree | Detail | |
<0.001 | Hydrothorax | Diagnostic values of vascular endothelial growth factor and epidermal growth fac... | BeFree | 25635424 | Detail |
<0.001 | hypercalcemia | NA | BeFree | Detail | |
0.003 | Hypercholesterolemia, Familial | NA | LHGDN | Detail | |
<0.001 | hyperparathyroidism | NA | BeFree | Detail | |
0.002 | Hyperparathyroidism, Secondary | NA | GAD | Detail | |
0.102 | Hyperplasia | NA | LHGDN,RGD | Detail | |
0.002 | Hypersensitivity | NA | GAD | Detail | |
0.080 | Hypertensive disease | NA | BeFree,RGD | Detail | |
0.002 | Hypopharyngeal Neoplasms | NA | GAD | Detail | |
<0.001 | Immunologic Deficiency Syndromes | NA | BeFree | Detail | |
0.080 | Inflammation | NA | RGD | Detail | |
<0.001 | Inflammatory Bowel Diseases | NA | BeFree | Detail | |
<0.001 | influenza | NA | BeFree | Detail | |
0.120 | Insulin resistance | NA | CTD_human | Detail | |
<0.001 | Intestinal Neoplasms | NA | BeFree | Detail | |
<0.001 | Intestinal Polyps | NA | BeFree | Detail | |
<0.001 | Keloid | NA | BeFree | Detail | |
<0.001 | actinic keratosis | NA | BeFree | Detail | |
0.003 | Kidney Diseases | NA | BeFree,LHGDN | Detail | |
0.003 | Kidney Neoplasm | NA | BeFree,GAD | Detail | |
0.003 | Polycystic Kidney Diseases | NA | BeFree,GAD | Detail | |
0.006 | Fibroid Tumor | NA | BeFree,LHGDN | Detail | |
0.003 | leukemia | NA | BeFree,LHGDN | Detail | |
0.003 | chronic lymphocytic leukemia | NA | BeFree,GAD | Detail | |
0.001 | Acute Erythroblastic Leukemia | NA | BeFree | Detail | |
0.001 | Leukemia, Myelocytic, Acute | NA | BeFree | Detail | |
0.002 | Myeloid Leukemia, Chronic | A common germline deletion in the BIM gene was recently shown to favor the produ... | BeFree | 25090024 | Detail |
<0.001 | acute promyelocytic leukemia | NA | BeFree | Detail | |
<0.001 | Leukoplakia | NA | BeFree | Detail | |
<0.001 | liver cirrhosis | By immunohistochemistry EGFR and TGF-α were overexpressed in HCC and cirrhotic c... | BeFree | 26279457 | Detail |
<0.001 | Liver diseases | NA | BeFree | Detail | |
0.006 | Liver neoplasms | NA | BeFree,GAD | Detail | |
0.082 | Lung diseases | NA | BeFree,RGD | Detail | |
0.083 | Chronic Obstructive Airway Disease | NA | BeFree,GAD,RGD | Detail | |
<0.001 | Lupus Vulgaris | NA | BeFree | Detail | |
<0.001 | Lupus Erythematosus, Discoid | NA | BeFree | Detail | |
0.003 | Lupus Erythematosus, Systemic | NA | BeFree,LHGDN | Detail | |
0.013 | Lymphatic Metastasis | MiR-133a expression was negatively correlated to lymphatic metastasis (r = -0.18... | BeFree,GAD | 25903369 | Detail |
0.001 | lymphoma | The initial set of trials will focus on different questions: (1) Exceptional Res... | BeFree | 24857062 | Detail |
<0.001 | Malabsorption Syndrome | Consistent with previous studies demonstrating a role for muscarinic and epiderm... | BeFree | 26210740 | Detail |
0.030 | Malignant neoplasm of stomach | The present study was to determine the role of KRAS status in EGFR antibody trea... | BeFree,GAD | 24467518 | Detail |
0.030 | Malignant neoplasm of stomach | Many molecular pathways are currently under investigation as therapeutic targets... | BeFree,GAD | 24587678 | Detail |
0.030 | Malignant neoplasm of stomach | These results support the involvement of EGFR and HER2 in gastric cancer and sug... | BeFree,GAD | 24728052 | Detail |
0.030 | Malignant neoplasm of stomach | Inhibition of epidermal growth factor receptor signaling prohibits metastasis of... | BeFree,GAD | 25085584 | Detail |
0.030 | Malignant neoplasm of stomach | Identification of EGFR expression status association with metastatic lymph node ... | BeFree,GAD | 25154973 | Detail |
0.030 | Malignant neoplasm of stomach | Patients with HER2(+) /EGFR(+) /MET(+) GCs had a substantial risk of death with ... | BeFree,GAD | 25157953 | Detail |
0.030 | Malignant neoplasm of stomach | Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. | BeFree,GAD | 25394504 | Detail |
0.030 | Malignant neoplasm of stomach | Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on... | BeFree,GAD | 25556597 | Detail |
0.030 | Malignant neoplasm of stomach | The prevalence of genomic copy number aberrations of epidermal growth factor rec... | BeFree,GAD | 25558650 | Detail |
0.030 | Malignant neoplasm of stomach | In addition, synergy in growth inhibition was observed when the GC cells were tr... | BeFree,GAD | 25576915 | Detail |
0.030 | Malignant neoplasm of stomach | The results demonstrated that EGFR phosphorylation was markedly inhibited in gas... | BeFree,GAD | 25625229 | Detail |
0.030 | Malignant neoplasm of stomach | Cetuximab, an immunoglobulin G1 chimeric monoclonal antibody directed against th... | BeFree,GAD | 25815786 | Detail |
0.030 | Malignant neoplasm of stomach | EGFR gene polymorphisms -216G>T and -191C>A are risk markers for gastric cancer ... | BeFree,GAD | 25867325 | Detail |
0.030 | Malignant neoplasm of stomach | In gastric cancer (GC), epidermal growth factor receptor (EGFR) overexpression a... | BeFree,GAD | 26318594 | Detail |
0.120 | Animal Mammary Neoplasms | NA | CTD_human | Detail | |
0.120 | Mammary Neoplasms, Experimental | NA | CTD_human | Detail | |
<0.001 | Marijuana Abuse | Higher expression of the EGFR cascade in cannabis smokers revealed that cannabis... | BeFree | 25736926 | Detail |
<0.001 | measles | NA | BeFree | Detail | |
0.002 | medulloblastoma | Overexpression of EGFR predicts poor outcomes of MBs, small cell GBMs and PNETs,... | BeFree | 24986561 | Detail |
0.023 | melanoma | Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cu... | BeFree,GAD,LHGDN | 25243790 | Detail |
0.023 | melanoma | An inverse relationship between MITF, vemurafenib resistance, and EGFR was then ... | BeFree,GAD,LHGDN | 25789707 | Detail |
<0.001 | multiple endocrine neoplasia type 2B | NA | BeFree | Detail | |
0.002 | meningioma | NA | BeFree | Detail | |
0.129 | Mesothelioma | Regarding that also EGFR amplifications in MPM are absolute rarities, our findin... | BeFree,CTD_human,LHGDN | 25138167 | Detail |
0.008 | Metaplasia | NA | LHGDN | Detail | |
<0.001 | Mixed Salivary Gland Tumor | NA | BeFree | Detail | |
0.001 | Monosomy | NA | BeFree | Detail | |
0.008 | Mouth Neoplasms | NA | GAD,LHGDN | Detail | |
<0.001 | multiple myeloma | Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose ... | BeFree | 25894462 | Detail |
<0.001 | Xeroderma Pigmentosum, Complementation Group D | The germline polymorphisms studied were thymidylate synthase, (VNTR/5'UTR, 2R G&... | BeFree | 21570215 | Detail |
<0.001 | Mycoplasma Infections | NA | BeFree | Detail | |
<0.001 | Nasal Polyps | NA | BeFree | Detail | |
0.120 | Nasopharyngeal Neoplasms | NA | CTD_human | Detail | |
0.002 | Neck Neoplasms | NA | BeFree | Detail | |
<0.001 | Neonatal hepatitis | NA | BeFree | Detail | |
0.122 | Neoplasm Invasiveness | NA | CTD_human,GAD | Detail | |
0.002 | rheumatoid arthritis | Association of PTPN22 rs2476601 and EGFR rs17337023 Gene polymorphisms and rheum... | BeFree | 23350658 | Detail |
0.134 | Neoplasm Recurrence, Local | NA | CTD_human,GAD | Detail | |
0.002 | Neoplasms, Glandular and Epithelial | NA | GAD | Detail | |
0.001 | nephroblastoma | NA | BeFree | Detail | |
<0.001 | Nesidioblastosis | NA | BeFree | Detail | |
0.005 | neurilemmoma | NA | BeFree,LHGDN | Detail | |
0.003 | neuroblastoma | Using the Snapshot assay, mutation statuses were detected for EGFR, Kirsten rate... | BeFree | 24823994 | Detail |
0.003 | neuroblastoma | Clinically, EGFR inhibitors are ineffective as single agent compounds in patient... | BeFree | 25756510 | Detail |
0.001 | neurofibroma | Transgenic mice heterozygous for a Trp53-null allele and overexpressing EGFR in ... | BeFree | 24832557 | Detail |
0.001 | neurofibromatosis 1 | NA | BeFree | Detail | |
0.006 | acoustic neuroma | NA | BeFree,LHGDN | Detail | |
<0.001 | Nevus | NA | BeFree | Detail | |
<0.001 | Melanocytic nevus | NA | BeFree | Detail | |
0.001 | Nodule | For overall patients, EGFR mutation status was associated with gender, pStage, p... | BeFree | 25605150 | Detail |
<0.001 | obesity | NA | BeFree | Detail | |
0.007 | oligodendroglioma | NA | BeFree,LHGDN | Detail | |
0.003 | Disorder of the optic nerve | NA | LHGDN | Detail | |
0.137 | osteosarcoma | Thus, miR-143, EGFR, and MMP9 are therapeutic targets for inhibiting OS invasion... | BeFree,CTD_human,GAD,LHGDN | 25227664 | Detail |
0.002 | Otorhinolaryngologic Neoplasms | NA | GAD | Detail | |
0.024 | ovarian carcinoma | Yes-associated protein (YAP) has been reported to be associated with the prognos... | BeFree | 24770679 | Detail |
0.024 | ovarian carcinoma | The crosstalk between PAFR and EGFR suggests a potentially important signaling l... | BeFree | 25261977 | Detail |
0.024 | ovarian carcinoma | miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibiti... | BeFree | 25299770 | Detail |
0.024 | ovarian carcinoma | We found that ErbB-1 was localized predominantly in the nucleus of ovarian cance... | BeFree | 25670170 | Detail |
0.024 | ovarian carcinoma | Of the two postulated miR-7 target genes we examined, BCL2, but not EGFR, seems ... | BeFree | 25862909 | Detail |
0.024 | ovarian carcinoma | Both epidermal growth factor receptor (EGFR) and fibroblast growth factor recept... | BeFree | 25919378 | Detail |
<0.001 | Ovarian Cysts | NA | BeFree | Detail | |
0.026 | Pancreatic Neoplasm | NA | BeFree,GAD,LHGDN | Detail | |
0.122 | papilloma | EGFR mutations were not identified in exophytic or oncocytic papillomas or non-I... | BeFree,CTD_human | 25931286 | Detail |
<0.001 | pericardial effusion | NA | BeFree | Detail | |
<0.001 | Peripheral neuropathy | NA | BeFree | Detail | |
<0.001 | Peripheral Nervous System Neoplasms | NA | BeFree | Detail | |
<0.001 | Peutz-Jeghers syndrome | NA | BeFree | Detail | |
<0.001 | pituitary adenoma | NA | BeFree | Detail | |
0.001 | Pituitary Diseases | NA | BeFree | Detail | |
0.004 | Pituitary Neoplasms | NA | BeFree,LHGDN | Detail | |
<0.001 | plague | NA | BeFree | Detail | |
0.006 | Pleural effusion disorder | It is feasible to detect the gene copy number of the pleural effusion cell mass ... | BeFree,GAD | 25635424 | Detail |
0.006 | Pleural effusion disorder | The results established the important role of HRM as a reliable and efficient me... | BeFree,GAD | 25674250 | Detail |
<0.001 | Pleural Neoplasms | NA | BeFree | Detail | |
<0.001 | Staphylococcal Pneumonia | NA | BeFree | Detail | |
<0.001 | Pneumoperitoneum | NA | BeFree | Detail | |
<0.001 | Adenomatous Polyposis Coli | NA | BeFree | Detail | |
0.001 | polyps | NA | BeFree | Detail | |
0.005 | Precancerous Conditions | NA | BeFree,GAD | Detail | |
<0.001 | Pregnancy Complications | NA | BeFree | Detail | |
<0.001 | prolactinoma | ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in fe... | BeFree | 25375038 | Detail |
0.144 | Prostatic Neoplasms | NA | BeFree,CTD_human,LHGDN | Detail | |
<0.001 | Prurigo | NA | BeFree | Detail | |
<0.001 | Pruritus | NA | BeFree | Detail | |
<0.001 | pterygium | NA | BeFree | Detail | |
0.082 | pulmonary fibrosis | NA | BeFree,RGD | Detail | |
<0.001 | pyruvate carboxylase deficiency disease | NA | BeFree | Detail | |
0.135 | Rectal Neoplasms | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
<0.001 | kidney failure | NA | BeFree | Detail | |
0.002 | retinoblastoma | Analysis of tumour samples and cell lines derived from resistant EGFR mutant pat... | BeFree | 25758528 | Detail |
<0.001 | Retroviridae Infections | NA | BeFree | Detail | |
0.001 | rhabdomyosarcoma | NA | BeFree | Detail | |
0.003 | rhinitis | NA | LHGDN | Detail | |
<0.001 | Salivary Gland Neoplasms | However, the results of phase II trials of EGFR inhibitors-as well as other targ... | BeFree | 26470903 | Detail |
<0.001 | schistosomiasis | NA | BeFree | Detail | |
<0.001 | Seizures | NA | BeFree | Detail | |
<0.001 | seminoma | NA | BeFree | Detail | |
<0.001 | Dermatologic disorders | NA | BeFree | Detail | |
0.004 | Skin Neoplasms | NA | BeFree,LHGDN | Detail | |
0.001 | Soft Tissue Neoplasms | NA | BeFree | Detail | |
<0.001 | Splenic Neoplasms | NA | BeFree | Detail | |
<0.001 | Staphylococcal Infections | NA | BeFree | Detail | |
<0.001 | Stereotyped Behavior | NA | BeFree | Detail | |
0.132 | Stomach Neoplasms | NA | BeFree,CTD_human,LHGDN | Detail | |
<0.001 | gastric ulcer | NA | BeFree | Detail | |
0.010 | synovial sarcoma | NA | BeFree,LHGDN | Detail | |
<0.001 | synovitis | NA | BeFree | Detail | |
<0.001 | Testicular Neoplasms | NA | BeFree | Detail | |
0.006 | thymoma | Does gefitinib have effects on EGFR mutation-positive thymoma? -Case report of t... | BeFree,LHGDN | 24492164 | Detail |
0.008 | Thyroid Neoplasm | NA | BeFree,GAD,LHGDN | Detail | |
0.080 | Tobacco use disorder | NA | RGD | Detail | |
0.002 | Tonsillar Neoplasms | NA | GAD | Detail | |
<0.001 | tonsillitis | NA | BeFree | Detail | |
<0.001 | trigeminal neuralgia | NA | BeFree | Detail | |
0.003 | Trisomy | NA | BeFree | Detail | |
<0.001 | tuberculosis | Gender-based impact of epidermal growth factor receptor mutation in patients wit... | BeFree | 25634180 | Detail |
<0.001 | Tuberculosis, Pulmonary | Comparing to male with pulmonary TB history, female with or without pulmonary TB... | BeFree | 25634180 | Detail |
<0.001 | tuberous sclerosis | NA | BeFree | Detail | |
<0.001 | Unipolar Depression | NA | BeFree | Detail | |
<0.001 | uremia | NA | BeFree | Detail | |
<0.001 | Uterine Fibroids | NA | BeFree | Detail | |
0.003 | Uterine Neoplasms | NA | BeFree,LHGDN | Detail | |
<0.001 | Zollinger-Ellison syndrome | NA | BeFree | Detail | |
<0.001 | B-Cell Lymphomas | Some miR-7 targets, including B-cell lymphoma 2 (BCL2) and epidermal growth fact... | BeFree | 25862909 | Detail |
0.010 | Pleural Effusion, Malignant | Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusi... | BeFree,GAD,LHGDN | 25239875 | Detail |
0.010 | Pleural Effusion, Malignant | Sea-urchin-like Au nanocluster with surface-enhanced raman scattering in detecti... | BeFree,GAD,LHGDN | 25495142 | Detail |
<0.001 | severe combined immunodeficiency | NA | BeFree | Detail | |
0.002 | Bronchial Hyperreactivity | NA | GAD | Detail | |
<0.001 | Central Nervous System Neoplasms | NA | BeFree | Detail | |
0.003 | hepatitis E | NA | LHGDN | Detail | |
<0.001 | Li-Fraumeni syndrome | EGFR-mutated lung cancer in Li-Fraumeni syndrome. | BeFree | 25047674 | Detail |
<0.001 | Li-Fraumeni syndrome | We report two cases of non-smoker patients diagnosed with EGFR-mutated lung aden... | BeFree | 25433984 | Detail |
<0.001 | Neurofibrillary degeneration (morphologic abnormality) | NA | BeFree | Detail | |
0.003 | Polycystic Kidney, Autosomal Dominant | NA | BeFree,LHGDN | Detail | |
0.120 | autosomal recessive polycystic kidney disease | NA | BeFree,CTD_human | Detail | |
<0.001 | Burning sensation | NA | BeFree | Detail | |
<0.001 | Alcohol abuse | NA | BeFree | Detail | |
<0.001 | cataract | NA | BeFree | Detail | |
<0.001 | benign neoplasm | NA | BeFree | Detail | |
<0.001 | Pancreatitis, Chronic | NA | BeFree | Detail | |
<0.001 | Epstein-Barr Virus Infections | NA | BeFree | Detail | |
0.080 | Left Ventricular Hypertrophy | NA | RGD | Detail | |
0.005 | Squamous cell carcinoma of lung | Finally, an inverse correlation was observed between Fhit and phospho-EGFR level... | BeFree | 24464917 | Detail |
0.005 | Squamous cell carcinoma of lung | The initial set of trials will focus on different questions: (1) Exceptional Res... | BeFree | 24857062 | Detail |
0.005 | Squamous cell carcinoma of lung | Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic sig... | BeFree | 25522678 | Detail |
0.005 | Squamous cell carcinoma of lung | We examined EGFR mutations in exons 19 and 21 in 147 NSCLC patients (excluding s... | BeFree | 25684509 | Detail |
0.005 | Squamous cell carcinoma of lung | Cell membrane CD44v6 levels in squamous cell carcinoma of the lung: association ... | BeFree | 25809603 | Detail |
0.005 | Squamous cell carcinoma of lung | Epidermal growth factor receptor gene mutation status in pure squamous-cell lung... | BeFree | 25886585 | Detail |
<0.001 | Humoral hypercalcemia of malignancy (disorder) | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma of rectum | NA | BeFree | Detail | |
0.003 | Oral Cavity Carcinoma | NA | BeFree,GAD | Detail | |
<0.001 | renal fibrosis | NA | BeFree | Detail | |
<0.001 | Cutaneous Melanoma | Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cu... | BeFree | 25243790 | Detail |
0.007 | esophageal carcinoma | Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitini... | BeFree | 25070024 | Detail |
0.009 | Malignant neoplasm of mouth | Inhibition of EGFR in pre-clinical models of oral pre-malignancies validates thi... | BeFree,GAD | 24412287 | Detail |
0.009 | Malignant neoplasm of mouth | Targeting Ley on EGFR could have a potential therapeutic effect on oral cancer. | BeFree,GAD | 25799278 | Detail |
0.001 | Malignant neoplasm of oropharynx | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of nasopharynx | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of anus | Anecdotal benefit from EGFR-targeted therapy has been reported in anal cancer an... | BeFree | 25244542 | Detail |
<0.001 | Malignant neoplasm of gallbladder | In conclusion, the present study indicated that the mechanism of action of miR-1... | BeFree | 25760482 | Detail |
<0.001 | uterine cancer | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of fallopian tube | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of testis | In this study, we analyzed the expression of MAGE-A, a cancer-testis antigen, in... | BeFree | 24866168 | Detail |
<0.001 | Malignant neoplasm of penis | NA | BeFree | Detail | |
0.005 | Malignant neoplasm of brain | NA | BeFree,GAD | Detail | |
0.004 | Secondary malignant neoplasm of lung | In multivariate analysis, lobulated margins (odds ratio, 4.815; 95% confidence i... | BeFree | 25575117 | Detail |
0.002 | Secondary malignant neoplasm of bone | Our findings support a model in which nuclear EGFR acts as a transcriptional rep... | BeFree | 26071255 | Detail |
<0.001 | Stage 0 Breast Carcinoma | NA | BeFree | Detail | |
<0.001 | Middle Ear Cholesteatoma | NA | BeFree | Detail | |
<0.001 | Christ-Siemens-Touraine syndrome | NA | BeFree | Detail | |
<0.001 | acute intermittent porphyria | NA | BeFree | Detail | |
<0.001 | Neurofibromatoses | NA | BeFree | Detail | |
<0.001 | Dermatitis, Allergic Contact | NA | BeFree | Detail | |
<0.001 | Russell-Silver syndrome | NA | BeFree | Detail | |
0.002 | Agenesis of corpus callosum | NA | BeFree | Detail | |
0.026 | Tumor Progression | Aberrant epidermal growth factor receptor (EGFR) signaling in non-small cell lun... | BeFree | 25174397 | Detail |
0.026 | Tumor Progression | ERBB2/HER2 belongs to the EGFR-family of receptor tyrosine kinases and its overe... | BeFree | 25596742 | Detail |
0.026 | Tumor Progression | One mechanism by which EGFR promotes tumor progression is by activating signal c... | BeFree | 25622907 | Detail |
0.026 | Tumor Progression | Epidermal growth factor receptor (EGFR) mutation is one of the hallmarks of canc... | BeFree | 25701783 | Detail |
0.026 | Tumor Progression | Activation of epidermal growth factor receptor (EGFR), which occurs in many type... | BeFree | 26280537 | Detail |
<0.001 | Adenocarcinoma, Tubular | NA | BeFree | Detail | |
<0.001 | Anaplastic carcinoma | NA | BeFree | Detail | |
<0.001 | Carcinoma, Spindle-Cell | NA | BeFree | Detail | |
<0.001 | Undifferentiated carcinoma | NA | BeFree | Detail | |
<0.001 | Carcinomatosis | NA | BeFree | Detail | |
<0.001 | Dysplastic Nevus | NA | BeFree | Detail | |
<0.001 | Germ cell tumor | NA | BeFree | Detail | |
<0.001 | Sarcoma, Epithelioid | NA | BeFree | Detail | |
0.003 | thymic carcinoma | NA | BeFree | Detail | |
0.004 | Lung Diseases, Interstitial | Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung dise... | BeFree | 24819665 | Detail |
0.004 | Lung Diseases, Interstitial | The frequency of interstitial lung disease (ILD) of grade ≥3 was low (0.6-2.2%) ... | BeFree | 25704957 | Detail |
<0.001 | Neuroectodermal Tumors | NA | BeFree | Detail | |
<0.001 | Lichen Planus, Oral | NA | BeFree | Detail | |
<0.001 | Leukoplakia, Hairy | NA | BeFree | Detail | |
0.009 | adenosquamous carcinoma | NA | BeFree,LHGDN | Detail | |
<0.001 | hepatoblastoma | NA | BeFree | Detail | |
<0.001 | pulmonary blastoma | NA | BeFree | Detail | |
<0.001 | endometrial stromal sarcoma | NA | BeFree | Detail | |
0.003 | angiomyolipoma | NA | BeFree,LHGDN | Detail | |
<0.001 | Giant Cell Tumor of Bone | NA | BeFree | Detail | |
0.003 | Sarcoma, Clear Cell | NA | BeFree,LHGDN | Detail | |
<0.001 | alveolar rhabdomyosarcoma | NA | BeFree | Detail | |
<0.001 | Rhabdomyosarcoma, Embryonal | NA | BeFree | Detail | |
0.003 | embryonal carcinoma | NA | BeFree,LHGDN | Detail | |
0.001 | Neuroectodermal Tumor, Primitive | Overexpression of EGFR predicts poor outcomes of MBs, small cell GBMs and PNETs,... | BeFree | 24986561 | Detail |
<0.001 | adrenal cortical adenoma | NA | BeFree | Detail | |
0.002 | Adenomatosis, Pulmonary | NA | GAD | Detail | |
<0.001 | Adenocarcinoma, Clear Cell | NA | BeFree | Detail | |
<0.001 | Follicular thyroid carcinoma | NA | BeFree | Detail | |
<0.001 | acinar cell carcinoma | NA | BeFree | Detail | |
0.121 | adrenocortical carcinoma | NA | BeFree,CTD_human | Detail | |
0.005 | mucoepidermoid carcinoma | NA | BeFree,LHGDN | Detail | |
<0.001 | Carcinoma, Neuroendocrine | We identified 126 EGFR-mutated (21.8% of 578 successful genotyped cases) lung ca... | BeFree | 25700797 | Detail |
0.132 | cholangiocarcinoma | In this review article, we discuss the molecular aspects of CCA including the ro... | BeFree,CTD_human,GAD,LHGDN | 24420749 | Detail |
0.002 | Cystadenocarcinoma, Mucinous | NA | GAD | Detail | |
0.003 | Cystadenocarcinoma, Serous | NA | BeFree,GAD | Detail | |
0.002 | Carcinoma, Giant Cell | NA | GAD | Detail | |
0.004 | Carcinoma, Large Cell | A significantly higher incidence of EGFR mutations was observed in bronchioloalv... | BeFree,GAD | 25684509 | Detail |
0.003 | verrucous carcinoma | NA | LHGDN | Detail | |
0.003 | Cervical Intraepithelial Neoplasia | NA | BeFree,GAD | Detail | |
<0.001 | ganglioglioma | NA | BeFree | Detail | |
<0.001 | ganglioneuroblastoma | NA | BeFree | Detail | |
0.002 | Squamous Cell Neoplasms | NA | GAD | Detail | |
0.003 | inverted papilloma | NA | BeFree,LHGDN | Detail | |
0.121 | gliosarcoma | NA | BeFree,ORPHANET | Detail | |
0.004 | Nerve Sheath Tumors | Transgenic mice heterozygous for a Trp53-null allele and overexpressing EGFR in ... | BeFree,LHGDN | 24832557 | Detail |
<0.001 | hemangioblastoma | NA | BeFree | Detail | |
<0.001 | Rhabdoid Tumor | NA | BeFree | Detail | |
0.004 | Neuroendocrine Tumors | NA | BeFree,LHGDN | Detail | |
<0.001 | childhood rhabdomyosarcoma | NA | BeFree | Detail | |
<0.001 | uveal melanoma | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of salivary gland | NA | BeFree | Detail | |
0.005 | Lip and oral cavity carcinoma | Inhibition of EGFR in pre-clinical models of oral pre-malignancies validates thi... | BeFree | 24412287 | Detail |
0.005 | Lip and oral cavity carcinoma | Targeting Ley on EGFR could have a potential therapeutic effect on oral cancer. | BeFree | 25799278 | Detail |
0.001 | Meningeal Carcinomatosis | Our case suggests that dual targeting of epidermal growth factor receptor (EGFR)... | BeFree | 24999085 | Detail |
<0.001 | Comedone | NA | BeFree | Detail | |
<0.001 | rapidly progressive glomerulonephritis | NA | BeFree | Detail | |
<0.001 | pituitary-dependent Cushing's disease | NA | BeFree | Detail | |
<0.001 | Lesion of brain | NA | BeFree | Detail | |
<0.001 | Neurologic Symptoms | It represents a potential therapeutic option against LM after failure of standar... | BeFree | 25921002 | Detail |
<0.001 | Thoracic lymphadenopathy | ALK positive lung adenocarcinomas are more likely than EGFR mutant lung adenocar... | BeFree | 25312988 | Detail |
0.001 | gallbladder carcinoma | In conclusion, the present study indicated that the mechanism of action of miR-1... | BeFree | 25760482 | Detail |
0.024 | pancreatic carcinoma | EGFR has been implicated in various malignancies such as NSCLC, breast, head and... | BeFree | 24921970 | Detail |
0.024 | pancreatic carcinoma | Together, these studies provide further support for a role for EGFR and HER2 in ... | BeFree | 25117978 | Detail |
0.024 | pancreatic carcinoma | Lumican plays a restrictive role in EGFR-expressing pancreatic cancer progressio... | BeFree | 25336691 | Detail |
0.024 | pancreatic carcinoma | Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human p... | BeFree | 25348515 | Detail |
0.024 | pancreatic carcinoma | In conclusion, our studies will enhance the translational acquaintance of pan-EG... | BeFree | 25686822 | Detail |
0.024 | pancreatic carcinoma | Moreover, EGFR was found to mediate the REG3A signal for PaC cell growth and JAK... | BeFree | 25779676 | Detail |
<0.001 | Carcinoma of male breast | NA | BeFree | Detail | |
<0.001 | fallopian tube carcinoma | NA | BeFree | Detail | |
0.008 | Gastrointestinal Stromal Tumors | Targeting c-Kit plus HER1 or AXL/c-Met abrogates IM resistance in GIST. | BeFree,LHGDN | 25557174 | Detail |
<0.001 | Lymphangitis carcinomatosa | NA | BeFree | Detail | |
0.005 | Cancer of Nasopharynx | NA | BeFree,GAD | Detail | |
<0.001 | Squamous cell carcinoma of penis | NA | BeFree | Detail | |
<0.001 | Female Pseudohermaphroditism | Localisation of PTPD1 at the plasma membrane was mediated by its FERM domain and... | BeFree | 25062045 | Detail |
0.002 | Anaplastic thyroid carcinoma | NA | BeFree | Detail | |
0.002 | Medullary carcinoma of thyroid | NA | BeFree | Detail | |
0.002 | Papillary thyroid carcinoma | NA | BeFree | Detail | |
0.001 | Fibrosis, Liver | In conclusion, miR-214 appears to participate in the development of hepatic fibr... | BeFree | 26122702 | Detail |
<0.001 | Squamous Papilloma of the Larynx | NA | BeFree | Detail | |
0.005 | Biliary calculi | NA | LHGDN | Detail | |
0.080 | Parkinsonian Disorders | NA | RGD | Detail | |
0.120 | Disease Progression | NA | CTD_human | Detail | |
<0.001 | Malignant neoplasm of male breast | NA | BeFree | Detail | |
<0.001 | Carcinoma, Lewis Lung | NA | BeFree | Detail | |
<0.001 | mixed gliomas | NA | BeFree | Detail | |
<0.001 | Carcinoma of ampulla of Vater | NA | BeFree | Detail | |
0.004 | Carcinoma, Small Cell | NA | BeFree,LHGDN | Detail | |
0.120 | Chloracne | NA | BeFree,CTD_human | Detail | |
<0.001 | Epithelial hyperplasia of skin | NA | BeFree | Detail | |
<0.001 | Disorder of skeletal system | NA | BeFree | Detail | |
<0.001 | Thickening of pleura | NA | BeFree | Detail | |
<0.001 | Greig cephalopolysyndactyly syndrome | NA | BeFree | Detail | |
<0.001 | Donohue syndrome | NA | BeFree | Detail | |
<0.001 | Xeroderma Pigmentosum, Complementation Group D | NA | BeFree | Detail | |
<0.001 | Simple renal cyst | NA | BeFree | Detail | |
<0.001 | Endometrioma | NA | BeFree | Detail | |
<0.001 | Parathyroid hyperplasia | NA | BeFree | Detail | |
<0.001 | Erythroblastosis | NA | BeFree | Detail | |
<0.001 | Rhinovirus infection | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of colon stage IV | NA | BeFree | Detail | |
0.005 | Carcinoma breast stage IV | Epidermal growth factor receptor overexpression is a predictive factor for trast... | BeFree | 25349977 | Detail |
0.005 | Carcinoma breast stage IV | Resistance to the human epidermal growth factor receptor (HER2)-targeted antibod... | BeFree | 25391374 | Detail |
0.005 | Carcinoma breast stage IV | The antitumorigenic function of EGFR in metastatic breast cancer is regulated by... | BeFree | 25622905 | Detail |
<0.001 | Breast cancer recurrent | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of stomach stage IV | NA | BeFree | Detail | |
<0.001 | Non-small cell lung cancer stage I | NA | BeFree | Detail | |
<0.001 | Non-small cell lung cancer stage III | To determine the frequency and clinical significance of epidermal growth factor ... | BeFree | 25442336 | Detail |
<0.001 | Metastatic osteosarcoma | NA | BeFree | Detail | |
<0.001 | Anal cancer recurrent | NA | BeFree | Detail | |
<0.001 | Cervical carcinoma stage IIB | NA | BeFree | Detail | |
0.002 | inflammatory breast carcinoma | NA | BeFree | Detail | |
<0.001 | Stage IV Ovarian Carcinoma | NA | BeFree | Detail | |
<0.001 | gastric adenocarcinoma | Chromosome 7 polysomy may be responsible for EGFR gene amplifications, and we co... | BeFree | 25558650 | Detail |
<0.001 | Recurrent Endometrial Cancer | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma of small intestine | Thus, we suggest that Musashi-1, Lgr5, and pEGFR are overexpressed in human SIAs... | BeFree | 25773390 | Detail |
<0.001 | Prostate cancer recurrent | NA | BeFree | Detail | |
<0.001 | Thymoma malignant invasive | NA | BeFree | Detail | |
<0.001 | adult glioblastoma | A randomised, open label phase III trial with nimotuzumab, an anti-epidermal gro... | BeFree | 25616647 | Detail |
<0.001 | Metastatic melanoma | NA | BeFree | Detail | |
<0.001 | Melanoma recurrent | An inverse relationship between MITF, vemurafenib resistance, and EGFR was then ... | BeFree | 25789707 | Detail |
0.026 | Cancer of Head and Neck | Targeting the epidermal growth factor receptor for head and neck cancer chemopre... | BeFree,GAD | 24412287 | Detail |
0.026 | Cancer of Head and Neck | Better anti-EGFR treatment efficacy was related to lower EGFR expression in head... | BeFree,GAD | 24780353 | Detail |
0.026 | Cancer of Head and Neck | Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and n... | BeFree,GAD | 25355701 | Detail |
0.026 | Cancer of Head and Neck | Effective therapeutic approach for head and neck cancer by an engineered minibod... | BeFree,GAD | 25438047 | Detail |
0.026 | Cancer of Head and Neck | MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth F... | BeFree,GAD | 25712126 | Detail |
0.026 | Cancer of Head and Neck | The EGFR-targeted antibody cetuximab is effective against head and neck cancer (... | BeFree,GAD | 25832655 | Detail |
0.001 | Liver and Intrahepatic Biliary Tract Carcinoma | NA | BeFree | Detail | |
<0.001 | Adenosquamous cell lung cancer | EGFR gene mutations in patients with adenosquamous lung carcinoma. | BeFree | 24575772 | Detail |
0.002 | Adenocarcinoma Of Esophagus | We show for the first time a significant treatment response to the EGFR tyrosine... | BeFree | 25070024 | Detail |
0.002 | Adenocarcinoma Of Esophagus | Epidermal growth factor receptor (EGFR) is an independent adverse prognostic fac... | BeFree | 25216514 | Detail |
<0.001 | anal carcinoma | Anecdotal benefit from EGFR-targeted therapy has been reported in anal cancer an... | BeFree | 25244542 | Detail |
0.003 | cervical squamous cell carcinoma | NA | BeFree,GAD | Detail | |
<0.001 | Transitional cell carcinoma of bladder | NA | BeFree | Detail | |
<0.001 | bladder adenocarcinoma | NA | BeFree | Detail | |
0.001 | Conventional (Clear Cell) Renal Cell Carcinoma | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma of salivary gland | NA | BeFree | Detail | |
<0.001 | extraosseous Ewings sarcoma-primitive neuroepithelial tumor | Overexpression of EGFR predicts poor outcomes of MBs, small cell GBMs and PNETs,... | BeFree | 24986561 | Detail |
<0.001 | Carcinoid tumor of lung | NA | BeFree | Detail | |
0.017 | Solid tumour | The initial set of trials will focus on different questions: (1) Exceptional Res... | BeFree | 24857062 | Detail |
0.017 | Solid tumour | Preclinical studies have shown synergism between epidermal growth factor recepto... | BeFree | 25590835 | Detail |
0.017 | Solid tumour | Cetuximab (anti-epidermal growth factor receptor - EGFR - monoclonal antibody) i... | BeFree | 25595386 | Detail |
0.017 | Solid tumour | Ubiquitous overexpression of wild type EGFR in many solid tumors has led to the ... | BeFree | 25658924 | Detail |
0.017 | Solid tumour | Eligible patients were aged at least 18 years with histologically confirmed, che... | BeFree | 26159065 | Detail |
0.002 | stage, non-small cell lung cancer | Molecular testing for epidermal growth factor receptor (EGFR) mutations is requi... | BeFree | 24831172 | Detail |
0.002 | stage, non-small cell lung cancer | Although surgical resection remains standard treatment for early stage non-small... | BeFree | 25152277 | Detail |
0.002 | stage, non-small cell lung cancer | Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsm... | BeFree | 25611026 | Detail |
0.002 | stage, non-small cell lung cancer | Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small ... | BeFree | 25702091 | Detail |
<0.001 | stage, pancreatic cancer | NA | BeFree | Detail | |
<0.001 | Squamous cell carcinoma of oropharynx | NA | BeFree | Detail | |
<0.001 | Squamous cell carcinoma of tonsil | NA | BeFree | Detail | |
0.003 | laryngeal squamous cell carcinoma | NA | BeFree | Detail | |
<0.001 | glottis squamous cell carcinoma | Biopsy specimens of patients with glottic squamous cell carcinoma and simple hyp... | BeFree | 25279714 | Detail |
<0.001 | high-grade childhood cerebral astrocytoma | NA | BeFree | Detail | |
<0.001 | uterine carcinosarcoma | NA | BeFree | Detail | |
0.001 | diffuse astrocytoma | NA | BeFree | Detail | |
<0.001 | Squamous cell carcinoma of vulva | NA | BeFree | Detail | |
0.003 | Adenocarcinoma of pancreas | NA | BeFree | Detail | |
0.003 | Prostatic Intraepithelial Neoplasias | NA | BeFree,LHGDN | Detail | |
0.007 | cervix carcinoma | Studies in cervical cancer indicate that E5 increases epidermal growth factor re... | BeFree | 25027574 | Detail |
0.007 | cervix carcinoma | FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and rep... | BeFree | 25151576 | Detail |
<0.001 | Dryness of eye | IL-6, IL-9, CCL24, CCL18, IL-10, IFN-γ, and CCL2 were highly increased (>6-fold)... | BeFree | 26200497 | Detail |
<0.001 | Tumor necrosis | NA | BeFree | Detail | |
0.001 | High-Grade Squamous Intraepithelial Lesions | NA | BeFree | Detail | |
<0.001 | Hyperplastic Polyp | NA | BeFree | Detail | |
0.001 | pleomorphic carcinoma | NA | BeFree | Detail | |
<0.001 | Combined small cell carcinoma | NA | BeFree | Detail | |
0.001 | Squamous cell carcinoma, metastatic | NA | BeFree | Detail | |
<0.001 | Lymphoepithelial carcinoma | NA | BeFree | Detail | |
<0.001 | Schneiderian papilloma | High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas A... | BeFree | 25931286 | Detail |
0.002 | adenocarcinoma in situ | Adenocarcinoma in situ showed significantly higher DPD mRNA levels and more EGFR... | BeFree | 24405586 | Detail |
0.002 | adenocarcinoma in situ | The remaining 26 quadruple-negative tumors were significantly associated with AA... | BeFree | 25361983 | Detail |
<0.001 | Adenocarcinoma, intestinal type | NA | BeFree | Detail | |
<0.001 | Fibrolamellar hepatocellular carcinoma | NA | BeFree | Detail | |
<0.001 | Carcinoid tumor no ICD-O subtype | NA | BeFree | Detail | |
0.001 | malignant fibrous histiocytoma | NA | BeFree | Detail | |
<0.001 | Teratoma, Malignant | NA | BeFree | Detail | |
<0.001 | Hydatidiform Mole, Partial | NA | BeFree | Detail | |
0.007 | anaplastic astrocytoma | NA | BeFree,GAD | Detail | |
0.001 | pilocytic astrocytoma | NA | BeFree | Detail | |
0.120 | giant cell glioblastoma | NA | ORPHANET | Detail | |
0.002 | anaplastic oligodendroglioma | NA | BeFree | Detail | |
0.001 | Adenocarcinoma of colon | NA | BeFree | Detail | |
<0.001 | Human papilloma virus infection | NA | BeFree | Detail | |
<0.001 | Asymptomatic human immunodeficiency virus infection | NA | BeFree | Detail | |
<0.001 | Carcinoma ex pleomorphic adenoma | NA | BeFree | Detail | |
0.007 | Malignant neoplasm of liver | FLC overexpresses EGFR in comparison to hepatocellular cancer, suggesting that E... | BeFree,GAD | 23676344 | Detail |
<0.001 | intrahepatic cholangiocarcinoma | NA | BeFree | Detail | |
<0.001 | Large cell carcinoma of lung | NA | BeFree | Detail | |
0.002 | malignant mesothelioma | NA | BeFree | Detail | |
<0.001 | Malignant Mesothelioma of Peritoneum | NA | BeFree | Detail | |
<0.001 | Breast Cancer, Familial | NA | BeFree | Detail | |
<0.001 | Endometrioid carcinoma ovary | NA | BeFree | Detail | |
<0.001 | cervical adenosquamous carcinoma | NA | BeFree | Detail | |
<0.001 | pituitary carcinoma | NA | BeFree | Detail | |
0.001 | Multiple malignancy | NA | BeFree | Detail | |
0.026 | Malignant neoplasm of pancreas | EGFR has been implicated in various malignancies such as NSCLC, breast, head and... | BeFree,GAD | 24921970 | Detail |
0.026 | Malignant neoplasm of pancreas | Together, these studies provide further support for a role for EGFR and HER2 in ... | BeFree,GAD | 25117978 | Detail |
0.026 | Malignant neoplasm of pancreas | Lumican plays a restrictive role in EGFR-expressing pancreatic cancer progressio... | BeFree,GAD | 25336691 | Detail |
0.026 | Malignant neoplasm of pancreas | Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human p... | BeFree,GAD | 25348515 | Detail |
0.026 | Malignant neoplasm of pancreas | In conclusion, our studies will enhance the translational acquaintance of pan-EG... | BeFree,GAD | 25686822 | Detail |
0.026 | Malignant neoplasm of pancreas | Moreover, EGFR was found to mediate the REG3A signal for PaC cell growth and JAK... | BeFree,GAD | 25779676 | Detail |
<0.001 | Disseminated Malignant Neoplasm | NA | BeFree | Detail | |
<0.001 | Early gastric cancer | Female gender, tumor size, lymphovascular invasion and EGFR overexpression were ... | BeFree | 25593477 | Detail |
0.002 | Squamous cell carcinoma of tongue | These results suggested that ADAM10 is important in regulating the proliferation... | BeFree | 25333745 | Detail |
0.001 | Helicobacter pylori (H. pylori) infection in conditions classified elsewhere and of unspecified site | Helicobacter pylori transactivates the epidermal growth factor receptor (EGFR) o... | BeFree | 25499189 | Detail |
<0.001 | Respiratory syncytial virus (RSV) infection in conditions classified elsewhere and of unspecified site | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm of vulva | NA | BeFree | Detail | |
0.034 | Malignant neoplasm of prostate | Recently, ETS-related gene (ERG) gene rearrangements, phosphatase tensin homolog... | BeFree,GAD | 24516518 | Detail |
0.034 | Malignant neoplasm of prostate | EGFR mediates docetaxel resistance in human castration-resistant prostate cancer... | BeFree,GAD | 24888374 | Detail |
0.034 | Malignant neoplasm of prostate | Human epidermal growth factor receptor family members (HER) such as EGFR and HER... | BeFree,GAD | 25000999 | Detail |
0.034 | Malignant neoplasm of prostate | We propose that the loss of miR-203 is a molecular link in the progression of pr... | BeFree,GAD | 25004126 | Detail |
0.034 | Malignant neoplasm of prostate | Among these modules, transcription Androgen Receptor (AR) nuclear signaling and ... | BeFree,GAD | 25080090 | Detail |
0.034 | Malignant neoplasm of prostate | Berberine targets epidermal growth factor receptor signaling to suppress prostat... | BeFree,GAD | 25394789 | Detail |
0.034 | Malignant neoplasm of prostate | In this manuscript, we will discuss an inducible EGFR model (v-ERB-B:ER) and its... | BeFree,GAD | 25453219 | Detail |
<0.001 | Hematologic Neoplasms | NA | BeFree | Detail | |
0.120 | Craniofacial Abnormalities | NA | CTD_human | Detail | |
<0.001 | dermatofibrosarcoma protuberans | NA | BeFree | Detail | |
<0.001 | Troyer syndrome | NA | BeFree | Detail | |
<0.001 | thrombophilia | NA | BeFree | Detail | |
<0.001 | Dysplastic oral leukoplakia | NA | BeFree | Detail | |
<0.001 | Idiopathic crescentic glomerulonephritis | NA | BeFree | Detail | |
<0.001 | Chronic rejection of renal transplant | NA | BeFree | Detail | |
0.003 | lupus erythematosus | NA | BeFree,GAD | Detail | |
<0.001 | Skeletal dysplasia | NA | BeFree | Detail | |
<0.001 | Anaplastic Oligoastrocytoma | NA | BeFree | Detail | |
0.006 | endometrial carcinoma | Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pa... | BeFree | 24811063 | Detail |
0.006 | endometrial carcinoma | These new findings about endometrial cancer suggest a potential for targeted the... | BeFree | 24820961 | Detail |
<0.001 | Respiratory distress | A 33-year-old pregnant mother exhibited a disseminated EGFR-mutated lung carcino... | BeFree | 24997732 | Detail |
0.003 | Secondary malignant neoplasm of liver | Patients with an EGFR mutation were more prone to having synchronous LM than pat... | BeFree | 25240517 | Detail |
<0.001 | Necrotizing Enterocolitis | NA | BeFree | Detail | |
<0.001 | Fibrosis of bile duct | NA | BeFree | Detail | |
0.002 | Recurrent tumor | NA | BeFree | Detail | |
<0.001 | Bilateral cataracts (disorder) | NA | BeFree | Detail | |
<0.001 | Neurodegenerative Disorders | NA | BeFree | Detail | |
0.015 | Malignant neoplasm of esophagus | NA | BeFree,GAD | Detail | |
0.005 | Thyroid carcinoma | NA | BeFree | Detail | |
0.001 | Oropharyngeal disorders | NA | BeFree | Detail | |
0.004 | Squamous cell carcinoma of skin | NA | BeFree,GAD | Detail | |
0.017 | Malignant glioma | Because STAT signaling is commonly activated in malignant gliomas as a result of... | BeFree | 25482928 | Detail |
0.017 | Malignant glioma | Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur... | BeFree | 25808866 | Detail |
<0.001 | Cerebral metastasis | NA | BeFree | Detail | |
<0.001 | Tonsillar Carcinoma | NA | BeFree | Detail | |
<0.001 | primary sclerosing cholangitis | Additionally, cholangiocytes from LPS-treated mouse livers and human primary scl... | BeFree | 25915403 | Detail |
0.002 | Squamous cell carcinoma of mouth | NA | BeFree | Detail | |
0.004 | Osteosarcoma of bone | Thus, miR-143, EGFR, and MMP9 are therapeutic targets for inhibiting OS invasion... | BeFree | 25227664 | Detail |
0.002 | Carcinoma of larynx | Higher expression of the EGFR cascade in cannabis smokers revealed that cannabis... | BeFree | 25736926 | Detail |
<0.001 | Leukemogenesis | NA | BeFree | Detail | |
0.001 | Tumor Initiation | NA | BeFree | Detail | |
0.026 | prostate carcinoma | Recently, ETS-related gene (ERG) gene rearrangements, phosphatase tensin homolog... | BeFree | 24516518 | Detail |
0.026 | prostate carcinoma | EGFR mediates docetaxel resistance in human castration-resistant prostate cancer... | BeFree | 24888374 | Detail |
0.026 | prostate carcinoma | Human epidermal growth factor receptor family members (HER) such as EGFR and HER... | BeFree | 25000999 | Detail |
0.026 | prostate carcinoma | We propose that the loss of miR-203 is a molecular link in the progression of pr... | BeFree | 25004126 | Detail |
0.026 | prostate carcinoma | Among these modules, transcription Androgen Receptor (AR) nuclear signaling and ... | BeFree | 25080090 | Detail |
0.026 | prostate carcinoma | Berberine targets epidermal growth factor receptor signaling to suppress prostat... | BeFree | 25394789 | Detail |
0.026 | prostate carcinoma | In this manuscript, we will discuss an inducible EGFR model (v-ERB-B:ER) and its... | BeFree | 25453219 | Detail |
0.001 | CARCINOMA OF VULVA | NA | BeFree | Detail | |
0.007 | Epithelial ovarian cancer | miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibiti... | BeFree,GAD | 25299770 | Detail |
0.002 | invasive cancer | NA | BeFree | Detail | |
0.008 | Progressive Neoplastic Disease | Despite the efficacy and superiority of EGFR TKIs over chemotherapy as first-lin... | BeFree | 25176972 | Detail |
0.002 | Refractory cancer | NA | BeFree | Detail | |
<0.001 | Sentinel node (disorder) | NA | BeFree | Detail | |
<0.001 | Stage IV Colorectal Cancer | Although KRAS mutation has a predictive role in stage IV colorectal cancer (CRC)... | BeFree | 24889488 | Detail |
<0.001 | Complete hydatidiform mole | NA | BeFree | Detail | |
0.080 | breast carcinoma | A new class of protein cancer biomarker candidates: differentially expressed spl... | BeFree | 24802673 | Detail |
0.080 | breast carcinoma | Complete pharmacologic EGFR/HER2 inhibition is required to reverse Src-dependent... | BeFree | 24887236 | Detail |
0.080 | breast carcinoma | This is a revised case report of a 52 year old Caucasian female with Li-Fraumeni... | BeFree | 25047674 | Detail |
0.080 | breast carcinoma | We suggest that TJE is a new potential reagent for EGFR-targeted therapy and ant... | BeFree | 25051266 | Detail |
0.080 | breast carcinoma | The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will be r... | BeFree | 25051360 | Detail |
0.080 | breast carcinoma | The epidermal growth factor receptor (EGFR) is a member of the ErbB family that ... | BeFree | 25140053 | Detail |
0.080 | breast carcinoma | Here, we report a proof-of-concept experiment demonstrating that small peptides ... | BeFree | 25220456 | Detail |
0.080 | breast carcinoma | Our results showed that CD44 expression was significantly increased by epidermal... | BeFree | 25269647 | Detail |
0.080 | breast carcinoma | Prognostic and predictive values of EGFR overexpression and EGFR copy number alt... | BeFree | 25349977 | Detail |
0.080 | breast carcinoma | In both the primary cancers and the metastases, Claudin-4 was most frequently ex... | BeFree | 25417118 | Detail |
0.080 | breast carcinoma | BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human ... | BeFree | 25417703 | Detail |
0.080 | breast carcinoma | Because mutations within HER1/EGFR are predictive of response to tyrosine kinase... | BeFree | 25435280 | Detail |
0.080 | breast carcinoma | Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast c... | BeFree | 25454348 | Detail |
0.080 | breast carcinoma | Coexpression of EGFR and HER2 has been associated with poor disease outcome, hig... | BeFree | 25510900 | Detail |
0.080 | breast carcinoma | While ERBB1, ERBB2 and ERBB3 are often overexpressed or activated in breast canc... | BeFree | 25516216 | Detail |
0.080 | breast carcinoma | We propose that miR-7 regulated pathways, including EGFR and Src kinase, represe... | BeFree | 25532106 | Detail |
0.080 | breast carcinoma | Estrogen-responsive genes most significantly influenced by cohesin were enriched... | BeFree | 25542856 | Detail |
0.080 | breast carcinoma | This study identifies mutant p53 as an essential player in ErbB2 and EGFR-mediat... | BeFree | 25573952 | Detail |
0.080 | breast carcinoma | TXNIP interaction with the Her-1/2 pathway contributes to overall survival in br... | BeFree | 25605021 | Detail |
0.080 | breast carcinoma | Lapatinib, a dual tyrosine kinase inhibitor that interrupts the epidermal growth... | BeFree | 25605188 | Detail |
0.080 | breast carcinoma | Amplified HER2, which encodes a member of the epidermal growth factor receptor (... | BeFree | 25605973 | Detail |
0.080 | breast carcinoma | Further understanding of the paradoxical function of EGFR between primary and me... | BeFree | 25622905 | Detail |
0.080 | breast carcinoma | Loss of catalytically functional PTPN14 increased the secretion of growth factor... | BeFree | 25690013 | Detail |
0.080 | breast carcinoma | More and more evidences demonstrate that androgen receptor (AR), epidermal growt... | BeFree | 25695063 | Detail |
0.080 | breast carcinoma | Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluore... | BeFree | 25702787 | Detail |
0.080 | breast carcinoma | A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 ac... | BeFree | 25766325 | Detail |
0.080 | breast carcinoma | To identify a prognostic signature for breast cancer, we performed DNA methylati... | BeFree | 25773928 | Detail |
0.080 | breast carcinoma | Kindlin-2 interacts with and stabilizes EGFR and is required for EGF-induced bre... | BeFree | 25790908 | Detail |
0.080 | breast carcinoma | Upregulation of HER3 has been found to be a major mechanism underlying drug resi... | BeFree | 25849870 | Detail |
0.080 | breast carcinoma | Endocrine therapy considerations in postmenopausal patients with hormone recepto... | BeFree | 25857348 | Detail |
0.080 | breast carcinoma | Correlation between p53 and epidermal growth factor receptor expression in breas... | BeFree | 25966200 | Detail |
0.080 | breast carcinoma | Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investig... | BeFree | 25969993 | Detail |
0.080 | breast carcinoma | Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced act... | BeFree | 26006730 | Detail |
0.080 | breast carcinoma | The majority of breast cancers present with estrogen receptor (ER)-positive and ... | BeFree | 26059247 | Detail |
0.080 | breast carcinoma | Thirty-two locally/systemically advanced breast cancers treated with first-line ... | BeFree | 26178788 | Detail |
0.001 | Ewings sarcoma-primitive neuroectodermal tumor (PNET) | Overexpression of EGFR predicts poor outcomes of MBs, small cell GBMs and PNETs,... | BeFree | 24986561 | Detail |
0.002 | Malignant neoplasm of gastrointestinal tract | NA | BeFree | Detail | |
0.003 | CNS metastases | Afatinib may therefore be an effective treatment for heavily pretreated patients... | BeFree | 25247337 | Detail |
0.014 | Secondary malignant neoplasm of lymph node | Moreover, the expression of miR-183-3p in tumor tissue was found to be associate... | BeFree | 24805982 | Detail |
0.014 | Secondary malignant neoplasm of lymph node | The overall analysis showed that higher expression of ALDH1A1 is associated with... | BeFree | 24938375 | Detail |
0.014 | Secondary malignant neoplasm of lymph node | Upregulation of EGFR expression is associated with lymph node metastases of GC, ... | BeFree | 25394504 | Detail |
0.014 | Secondary malignant neoplasm of lymph node | Female gender, tumor size, lymphovascular invasion and EGFR overexpression were ... | BeFree | 25593477 | Detail |
0.014 | Secondary malignant neoplasm of lymph node | Both Univariate (U) and COX multivariate (C) analyses revealed that high EGFR an... | BeFree | 25702787 | Detail |
0.014 | Secondary malignant neoplasm of lymph node | The COX-2(+)/EGFR(+) group was associated with tumor size (p=0.002), mitotic ind... | BeFree | 25964576 | Detail |
0.014 | Secondary malignant neoplasm of lymph node | TNBC had a lower lymph node metastasis rate but higher CK5/6 and EGFR expression... | BeFree | 25966200 | Detail |
0.025 | colon carcinoma | Here we show a clear correlation between the efficacy of anti-EGFR inhibitors wi... | BeFree | 24556630 | Detail |
0.025 | colon carcinoma | These results indicate that ERBB3 is a potential target for EGFR- and ERBB2-resi... | BeFree | 24970817 | Detail |
0.025 | colon carcinoma | Importantly, hyperactivation of SRC/EGFR signaling triggered by loss of PTPRO le... | BeFree | 25301722 | Detail |
0.025 | colon carcinoma | To elucidate the role of HMGA1 proteins in chemoresistance we analyzed resistanc... | BeFree | 25409711 | Detail |
0.025 | colon carcinoma | EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon ... | BeFree | 25535899 | Detail |
0.025 | colon carcinoma | KRAS mutations also induce anti-EGFR antibody resistance in adenocarcinoma such ... | BeFree | 25589625 | Detail |
0.025 | colon carcinoma | Mutations at the K-RAS locus in colon cancer cells are frequently associated wit... | BeFree | 25675084 | Detail |
0.025 | colon carcinoma | In contrast, forced expression of MITF in melanoma and colon cancer cells inhibi... | BeFree | 25789707 | Detail |
0.025 | colon carcinoma | Treatment of metastatic colon carcinoma with the anti-epidermal growth factor re... | BeFree | 25975014 | Detail |
0.022 | stomach carcinoma | The present study was to determine the role of KRAS status in EGFR antibody trea... | BeFree | 24467518 | Detail |
0.022 | stomach carcinoma | Many molecular pathways are currently under investigation as therapeutic targets... | BeFree | 24587678 | Detail |
0.022 | stomach carcinoma | These results support the involvement of EGFR and HER2 in gastric cancer and sug... | BeFree | 24728052 | Detail |
0.022 | stomach carcinoma | Inhibition of epidermal growth factor receptor signaling prohibits metastasis of... | BeFree | 25085584 | Detail |
0.022 | stomach carcinoma | Identification of EGFR expression status association with metastatic lymph node ... | BeFree | 25154973 | Detail |
0.022 | stomach carcinoma | Patients with HER2(+) /EGFR(+) /MET(+) GCs had a substantial risk of death with ... | BeFree | 25157953 | Detail |
0.022 | stomach carcinoma | Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. | BeFree | 25394504 | Detail |
0.022 | stomach carcinoma | Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on... | BeFree | 25556597 | Detail |
0.022 | stomach carcinoma | The prevalence of genomic copy number aberrations of epidermal growth factor rec... | BeFree | 25558650 | Detail |
0.022 | stomach carcinoma | In addition, synergy in growth inhibition was observed when the GC cells were tr... | BeFree | 25576915 | Detail |
0.022 | stomach carcinoma | The results demonstrated that EGFR phosphorylation was markedly inhibited in gas... | BeFree | 25625229 | Detail |
0.022 | stomach carcinoma | Cetuximab, an immunoglobulin G1 chimeric monoclonal antibody directed against th... | BeFree | 25815786 | Detail |
0.022 | stomach carcinoma | EGFR gene polymorphisms -216G>T and -191C>A are risk markers for gastric cancer ... | BeFree | 25867325 | Detail |
0.022 | stomach carcinoma | In gastric cancer (GC), epidermal growth factor receptor (EGFR) overexpression a... | BeFree | 26318594 | Detail |
0.014 | Carcinoma of bladder | EGFR as a potential therapeutic target for a subset of muscle-invasive bladder c... | BeFree | 25009231 | Detail |
0.014 | Carcinoma of bladder | Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-su... | BeFree | 25405368 | Detail |
0.014 | Carcinoma of bladder | The epidermal growth factor receptor (EGFR) family is reportedly overexpressed i... | BeFree | 25482142 | Detail |
<0.001 | skin carcinoma | NA | BeFree | Detail | |
0.003 | Central neuroblastoma | Using the Snapshot assay, mutation statuses were detected for EGFR, Kirsten rate... | BeFree | 24823994 | Detail |
0.003 | Central neuroblastoma | Clinically, EGFR inhibitors are ineffective as single agent compounds in patient... | BeFree | 25756510 | Detail |
0.004 | Dissecting aneurysm of the thoracic aorta | To show additional prognostic information about the mutational profile and new I... | BeFree | 25833149 | Detail |
0.004 | Dissecting aneurysm of the thoracic aorta | A prospective, multicentre phase II trial of low-dose erlotinib in non-small cel... | BeFree | 26174465 | Detail |
<0.001 | Carcinoma of glottis | The aim of the present study was to examine EGFR on protein level, confronting c... | BeFree | 25279714 | Detail |
<0.001 | bile duct carcinoma | NA | BeFree | Detail | |
<0.001 | germ cell cancer | NA | BeFree | Detail | |
0.004 | Malignant neoplasm of kidney | Lung and renal cancer, two areas in which huge progress has been made in the las... | BeFree | 25338550 | Detail |
0.004 | Malignant neoplasm of kidney | Molecular interaction of a kinase inhibitor midostaurin with anticancer drug tar... | BeFree | 25789858 | Detail |
<0.001 | cervical cancer metastasis | NA | BeFree | Detail | |
<0.001 | early pregnancy | The epidermal growth factor receptor critically regulates endometrial function d... | BeFree | 24945252 | Detail |
<0.001 | Multiple Pulmonary Nodules | NA | BeFree | Detail | |
<0.001 | Arnold-Chiari Malformation, Type I | NA | BeFree | Detail | |
0.003 | biliary tract cancer | TCDC also increased the expression of epidermal growth factor receptor (EGFR) li... | BeFree | 24839254 | Detail |
<0.001 | Brain Tumor, Primary | NA | BeFree | Detail | |
<0.001 | Primary malignant neoplasm of brain | NA | BeFree | Detail | |
0.004 | Well Differentiated Oligodendroglioma | NA | BeFree | Detail | |
<0.001 | Malignant neoplasm tonsil | NA | BeFree | Detail | |
<0.001 | lymphangioleiomyomatosis | Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model... | BeFree | 25699271 | Detail |
0.002 | Malignant Squamous Cell Neoplasm | NA | BeFree | Detail | |
<0.001 | peripheral nerve sheath neoplasm | NA | BeFree | Detail | |
0.004 | malignant peripheral nerve sheath tumor | Transgenic mice heterozygous for a Trp53-null allele and overexpressing EGFR in ... | BeFree | 24832557 | Detail |
0.003 | malignant pleural mesothelioma | Next, the identification of less EGFR mutations in the EGFR gene of the pleural ... | BeFree | 25679064 | Detail |
<0.001 | Helicobacter pylori infection | NA | BeFree | Detail | |
0.001 | Smoker's lung | NA | BeFree | Detail | |
<0.001 | In situ cancer | NA | BeFree | Detail | |
<0.001 | penis carcinoma | NA | BeFree | Detail | |
0.003 | Invasive breast carcinoma | NA | BeFree | Detail | |
<0.001 | Metastases to adrenals | NA | BeFree | Detail | |
0.002 | Rhabdoid Tumor of the Kidney | RTK expression (c-Kit, c-Met, AXL, HER-1, HER-2, IGF-1R) in pre-/post-imatinib (... | BeFree | 25557174 | Detail |
<0.001 | Lung adenocarcinoma recurrent | NA | BeFree | Detail | |
0.001 | Adenocarcinoma of lung, stage I | Correlations Between the EGFR Mutation Status and Clinicopathological Features o... | BeFree | 26496308 | Detail |
<0.001 | Recurrent Lung Carcinoma Cell Type Unspecified | NA | BeFree | Detail | |
<0.001 | breast adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Pancreatic adenocarcinoma metastatic | NA | BeFree | Detail | |
<0.001 | Recurrent lung cancer | NA | BeFree | Detail | |
<0.001 | Lung cancer stage I | NA | BeFree | Detail | |
0.001 | Advanced cancer | The initial set of trials will focus on different questions: (1) Exceptional Res... | BeFree | 24857062 | Detail |
<0.001 | Intraepithelial Neoplasia | NA | BeFree | Detail | |
<0.001 | Stromal Neoplasm | NA | BeFree | Detail | |
0.158 | ovarian neoplasm | NA | BeFree,CTD_human,GAD,LHGDN | Detail | |
<0.001 | cancer recurrence | NA | BeFree | Detail | |
0.001 | Metastatic Prostate Carcinoma | Activation of EGFR signaling pathway leads to prostate cancer bone metastasis; h... | BeFree | 25004126 | Detail |
<0.001 | precancerous lesions | NA | BeFree | Detail | |
0.005 | Acute coronary syndrome | NA | BeFree,GAD,LHGDN | Detail | |
<0.001 | salivary gland carcinoma | NA | BeFree | Detail | |
<0.001 | Hurthle Cell Tumor | NA | BeFree | Detail | |
0.002 | Papillomavirus Infections | NA | GAD | Detail | |
<0.001 | Arthritis, Collagen-Induced | NA | BeFree | Detail | |
0.120 | Arthritis, Experimental | NA | CTD_human | Detail | |
<0.001 | Bronchial dysplasia | NA | BeFree | Detail | |
0.001 | Invasive Ductal Breast Carcinoma | Strong adverse effect of epidermal growth factor receptor 2 overexpression on pr... | BeFree | 25804795 | Detail |
<0.001 | Gestational Trophoblastic Neoplasms | NA | BeFree | Detail | |
0.021 | Malignant neoplasm of ovary | Yes-associated protein (YAP) has been reported to be associated with the prognos... | BeFree | 24770679 | Detail |
0.021 | Malignant neoplasm of ovary | The crosstalk between PAFR and EGFR suggests a potentially important signaling l... | BeFree | 25261977 | Detail |
0.021 | Malignant neoplasm of ovary | We found that ErbB-1 was localized predominantly in the nucleus of ovarian cance... | BeFree | 25670170 | Detail |
0.021 | Malignant neoplasm of ovary | Of the two postulated miR-7 target genes we examined, BCL2, but not EGFR, seems ... | BeFree | 25862909 | Detail |
0.021 | Malignant neoplasm of ovary | Both epidermal growth factor receptor (EGFR) and fibroblast growth factor recept... | BeFree | 25919378 | Detail |
<0.001 | respiratory failure | NA | BeFree | Detail | |
0.001 | endometrial adenocarcinoma | NA | BeFree | Detail | |
0.004 | Skin toxicity | Gene regulatory biomarker identification for skin toxicities induced by EGFR inh... | BeFree | 26521924 | Detail |
<0.001 | High-Grade Prostatic Intraepithelial Neoplasia | NA | BeFree | Detail | |
0.163 | Squamous cell carcinoma of the head and neck | HRAS mutations and resistance to the epidermal growth factor receptor tyrosine k... | BeFree,CLINVAR | 24123531 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | If ultimately shown to reduce the risk of oral cancer, chemoprevention with EGFR... | BeFree,CLINVAR | 24412287 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | Influence of epidermal growth factor receptor expression on the cetuximab and pa... | BeFree,CLINVAR | 24780353 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head a... | BeFree,CLINVAR | 24927258 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | Targeted therapy against the epidermal growth factor receptor (EGFR) only variab... | BeFree,CLINVAR | 24993889 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | The tumor antigen (TA)-targeted monoclonal antibodies (mAb) cetuximab and panitu... | BeFree,CLINVAR | 24997207 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | These findings underscore the importance of ADAM17 and suggest that D1(A12) migh... | BeFree,CLINVAR | 25013379 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | The expression and subcellular localization of β-catenin and EGFR activation wer... | BeFree,CLINVAR | 25209444 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase r... | BeFree,CLINVAR | 25255959 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | We investigated the effects of cetuximab (EGFR antibody) and IMC-A12 (IGF-1R ant... | BeFree,CLINVAR | 25355701 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | Identification of epidermal growth factor receptor (EGFR) genetic variants that ... | BeFree,CLINVAR | 25511740 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | We show that upon EGF stimulation, EGFR and RhoC were strongly activated in HNSC... | BeFree,CLINVAR | 25622907 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | Further, large scale automated alignment of sequencing are unlikely to identify ... | BeFree,CLINVAR | 25658924 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | However, many patients with HNSCC respond poorly to the EGFR inhibitors (EGFRI) ... | BeFree,CLINVAR | 25712126 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | Epidermal growth factor receptor (EGFR) and its downstream elements are overexpr... | BeFree,CLINVAR | 25736926 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | Cetuximab is the only approved molecular targeting agent for HNSCC and despite u... | BeFree,CLINVAR | 25826749 | Detail |
0.163 | Squamous cell carcinoma of the head and neck | To date, cetuximab is the only FDA-approved anti-epidermal growth factor recepto... | BeFree,CLINVAR | 25967534 | Detail |
0.001 | Ductal Carcinoma | Breast cancer 1 (BRCA1)-associated breast cancers are mostly basal-like high-gra... | BeFree | 25417703 | Detail |
0.001 | Ductal Carcinoma | Short telomere lengths have been previously associated with triple-negative and ... | BeFree | 26092192 | Detail |
<0.001 | Mammary Carcinoma, Human | NA | BeFree | Detail | |
<0.001 | Dendritic Cell Sarcoma, Follicular | NA | BeFree | Detail | |
0.012 | sarcoma | EGFR (exons 18-21) and Kirsten RNA-associated rat sarcoma 2 virus (exon 2) mutat... | BeFree,LHGDN | 24993594 | Detail |
0.012 | sarcoma | Compared with patients with ALK(-) lung adenocarcinomas (33 patients; 12 with ep... | BeFree,LHGDN | 25557162 | Detail |
<0.001 | large cell neuroendocrine carcinoma | De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas... | BeFree | 25700797 | Detail |
<0.001 | Non-small cell carcinoma | NA | BeFree | Detail | |
<0.001 | Nonseminomatous germ cell tumor | NA | BeFree | Detail | |
<0.001 | major depressive disorder | NA | BeFree | Detail | |
<0.001 | Multiple basal cell papillomata | NA | BeFree | Detail | |
<0.001 | acute interstitial pneumonia | NA | BeFree | Detail | |
<0.001 | Disorder of skull | NA | BeFree | Detail | |
0.002 | Single tumor | Thus, the association between diverse activating mutations in EGFR and other sub... | BeFree | 24893890 | Detail |
0.002 | Single tumor | Surprisingly, the authors identify convergent evolution of multiple, mutually ex... | BeFree | 25092745 | Detail |
<0.001 | Salivary duct carcinoma | NA | BeFree | Detail | |
<0.001 | Adenoma of large intestine | NA | BeFree | Detail | |
<0.001 | Low Grade Squamous Intraepithelial Neoplasia | NA | BeFree | Detail | |
<0.001 | ACTH-secreting pituitary adenoma | NA | BeFree | Detail | |
<0.001 | Astrocytoma, low grade | NA | BeFree | Detail | |
<0.001 | Liver regeneration disorder | NA | BeFree | Detail | |
<0.001 | Asthmatic bronchitis | NA | BeFree | Detail | |
0.003 | Adenocarcinoma of large intestine | The aim of this study was to compare colorectal adenocarcinoma with mucinous com... | BeFree | 25907382 | Detail |
<0.001 | Squamous cell carcinoma of pharynx | NA | BeFree | Detail | |
<0.001 | Anaplastic large B-cell lymphoma | EGFR(epidermal growth factor receptor) mutations and ALK(anaplastic lymphoma kin... | BeFree | 24727987 | Detail |
<0.001 | Thymoma, type C | NA | BeFree | Detail | |
0.001 | Hormone refractory prostate cancer | NA | BeFree | Detail | |
<0.001 | adult astrocytic tumors | NA | BeFree | Detail | |
<0.001 | Cerebellar Glioblastoma | All of the cases of six cerebellar GBMs were p53‑positive and EGFR‑negative, as ... | BeFree | 25199771 | Detail |
<0.001 | Esophageal Basaloid Carcinoma | NA | BeFree | Detail | |
<0.001 | Hereditary Nonpolyposis Colorectal Cancer | NA | BeFree | Detail | |
<0.001 | Infiltrating Cervical Carcinoma | NA | BeFree | Detail | |
<0.001 | Invasive Apocrine Breast Carcinoma | NA | BeFree | Detail | |
<0.001 | Invasive Carcinoma | NA | BeFree | Detail | |
<0.001 | Infiltrating Bladder Urothelial Carcinoma | NA | BeFree | Detail | |
<0.001 | pulmonary sclerosing hemangioma | NA | BeFree | Detail | |
<0.001 | Malignant Mixed Mesodermal (Mullerian) Tumor | NA | BeFree | Detail | |
<0.001 | Malignant Phyllodes Tumor of Prostate | NA | BeFree | Detail | |
<0.001 | Metaplastic breast carcinoma | NA | BeFree | Detail | |
<0.001 | Mucinous Neoplasm | NA | BeFree | Detail | |
<0.001 | Ovarian Serous Adenocarcinoma | Ovarian serous carcinomas (n=112) and solid metastases (n=63; total=175) were an... | BeFree | 26232338 | Detail |
0.005 | pancreatic ductal adenocarcinoma | Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt onco... | BeFree | 24895459 | Detail |
0.005 | pancreatic ductal adenocarcinoma | Previous studies have demonstrated that combinatorial treatment of PDAC xenograf... | BeFree | 25117978 | Detail |
0.005 | pancreatic ductal adenocarcinoma | Inactivating Sox9 expression in mice confirmed its role in PDAC initiation; it d... | BeFree | 25336113 | Detail |
0.005 | pancreatic ductal adenocarcinoma | These results suggest that dysregulation of ubiquitination is a key mechanism of... | BeFree | 25348515 | Detail |
0.005 | pancreatic ductal adenocarcinoma | (i) hERG1 was expressed at high levels in 59% of primary PDAC; (ii) hERG1 blocka... | BeFree | 25719829 | Detail |
0.005 | pancreatic ductal adenocarcinoma | Proteomic analysis evidenced that MEK1 inhibition was accompanied by a sustained... | BeFree | 25736685 | Detail |
<0.001 | Mucoepidermoid carcinoma of parotid gland | NA | BeFree | Detail | |
<0.001 | periampullary adenocarcinoma | NA | BeFree | Detail | |
<0.001 | Prostate Phyllodes Tumor | NA | BeFree | Detail | |
0.001 | Primary Carcinoma | NA | BeFree | Detail | |
<0.001 | Squamous Lung Dysplasia | NA | BeFree | Detail | |
<0.001 | Stage IB Lung Adenocarcinoma | We proposed to investigate the distribution of concurrent oncogene mutations in ... | BeFree | 25546673 | Detail |
<0.001 | Supratentorial Glioblastoma | NA | BeFree | Detail | |
<0.001 | supratentorial primitive neuroectodermal tumor | NA | BeFree | Detail | |
<0.001 | differentiated thyroid gland carcinoma | NA | BeFree | Detail | |
<0.001 | pineal parenchymal tumor of intermediate differentiation | NA | BeFree | Detail | |
<0.001 | Mixed Neoplasm | NA | BeFree | Detail | |
<0.001 | Hypopharyngeal Carcinoma | NA | BeFree | Detail | |
0.006 | Epithelioma | NA | BeFree | Detail | |
<0.001 | mature teratoma | NA | BeFree | Detail | |
<0.001 | Anal cancer metastatic | NA | BeFree | Detail | |
<0.001 | Granulosa cell tumor of the ovary | NA | BeFree | Detail | |
<0.001 | Liposarcoma, well differentiated | NA | BeFree | Detail | |
0.001 | peritoneal mesothelioma | EGFR mutations were previously found in patients suffering from peritoneal mesot... | BeFree | 25679064 | Detail |
<0.001 | Pleural Mesothelioma | Next, the identification of less EGFR mutations in the EGFR gene of the pleural ... | BeFree | 25679064 | Detail |
0.004 | renal carcinoma | Lung and renal cancer, two areas in which huge progress has been made in the las... | BeFree | 25338550 | Detail |
0.004 | renal carcinoma | Molecular interaction of a kinase inhibitor midostaurin with anticancer drug tar... | BeFree | 25789858 | Detail |
<0.001 | Metastatic Carcinoma | NA | BeFree | Detail | |
<0.001 | Primary Lesion | In addition to the well-known characteristics of patients carrying EGFR mutation... | BeFree | 25442336 | Detail |
<0.001 | anal squamous cell carcinoma | NA | BeFree | Detail | |
<0.001 | Benign melanocytic nevus | NA | BeFree | Detail | |
0.215 | Mammary Neoplasms | For example, CDH3 was significantly up-regulated in the stromals of both breast ... | BeFree,CTD_human,GAD,LHGDN | 25826086 | Detail |
0.215 | Mammary Neoplasms | Positive Interplay Between CD3+ T-lymphocytes and Concurrent COX-2/EGFR Expressi... | BeFree,CTD_human,GAD,LHGDN | 25964576 | Detail |
<0.001 | Breast Cancer Model | Epidermal growth factor-receptor activation modulates Src-dependent resistance t... | BeFree | 24887236 | Detail |
0.001 | Hepatocarcinogenesis | Impact of epidermal growth factor receptor and transforming growth factor-α on h... | BeFree | 26279457 | Detail |
<0.001 | Mammary Tumorigenesis | Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promot... | BeFree | 25573952 | Detail |
0.003 | Primary Glioblastoma | Correlation between EGFR amplification and the expression of microRNA-200c in pr... | BeFree | 25058589 | Detail |
<0.001 | Primary Peritoneal Carcinoma | NA | BeFree | Detail | |
<0.001 | Prostate Basal Cell Carcinoma | Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss o... | BeFree | 25870120 | Detail |
0.002 | Cancer Cell Growth | NA | BeFree | Detail | |
<0.001 | Secondary Glioblastoma | NA | BeFree | Detail | |
<0.001 | Tumor-Associated Vasculature | NA | BeFree | Detail | |
0.003 | Tumor Angiogenesis | In this study, the role of EGFR in tumor angiogenesis was examined in H292 NSCLC... | BeFree | 25272226 | Detail |
0.003 | Tumor Angiogenesis | EGFR is involved in the tumor angiogenesis of HNSCC via the HIF-1α and Notch1 pa... | BeFree | 25723392 | Detail |
0.008 | Xenograft Model | Association of EGFR expression level and cetuximab activity in patient-derived x... | BeFree | 24947928 | Detail |
0.008 | Xenograft Model | Moreover, combined therapeutic inhibition of EGFR and c-Kit may abrogate this ac... | BeFree | 25510664 | Detail |
0.008 | Xenograft Model | In vivo studies using mouse xenograft models of CRC showed that Erbin promotes t... | BeFree | 25521828 | Detail |
0.008 | Xenograft Model | We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an ex... | BeFree | 25522765 | Detail |
<0.001 | Ductal Breast Carcinoma | Breast cancer 1 (BRCA1)-associated breast cancers are mostly basal-like high-gra... | BeFree | 25417703 | Detail |
<0.001 | Ductal Breast Carcinoma | Short telomere lengths have been previously associated with triple-negative and ... | BeFree | 26092192 | Detail |
0.001 | Neoplasms, Intracranial | Approaches used in this investigation include: bioluminescence imaging (BLI) for... | BeFree | 25313012 | Detail |
<0.001 | Rectal Tumors | NA | BeFree | Detail | |
0.003 | Rash and Dermatitis Adverse Event Associated with Chemoradiation | NA | BeFree | Detail | |
<0.001 | Non-Malignant Ascites Adverse Event | NA | BeFree | Detail | |
<0.001 | Chronic Kidney Diseases | NA | BeFree | Detail | |
<0.001 | Adenocarcinoma, Endometrioid | NA | BeFree | Detail | |
0.031 | Glioblastoma multiforme | Interestingly, the extent of these SHP2 signaling regulatory functions is dimini... | BeFree,GAD | 24951116 | Detail |
0.031 | Glioblastoma multiforme | These findings may explain reports on the common occurrence of mutant EGFR (EGFR... | BeFree,GAD | 25053824 | Detail |
0.031 | Glioblastoma multiforme | Whole genome sequencing of glioblastoma multiforme identifies multiple structura... | BeFree,GAD | 25103728 | Detail |
0.031 | Glioblastoma multiforme | Although EGFR phosphorylation and STAT3 activation are essential for the mainten... | BeFree,GAD | 25313011 | Detail |
0.031 | Glioblastoma multiforme | Tf-NP-miR-1 treatment on GBM spheres significantly inhibited migration of GBM sp... | BeFree,GAD | 25374033 | Detail |
0.031 | Glioblastoma multiforme | Together with our previous findings, these data suggest that GRh2 may suppress G... | BeFree,GAD | 25431263 | Detail |
0.031 | Glioblastoma multiforme | EGFR gene amplification also represents a signature of genetic abnormality in GB... | BeFree,GAD | 25576921 | Detail |
0.031 | Glioblastoma multiforme | Elevated expression of Notch-1 and EGFR induced apoptosis in glioblastoma multif... | BeFree,GAD | 25704190 | Detail |
0.031 | Glioblastoma multiforme | A common characteristic of glioblastoma multiforme histology is EGFR amplificati... | BeFree,GAD | 25760022 | Detail |
0.031 | Glioblastoma multiforme | Endogenous expressions of EGFR in various GBM cells were determined by western b... | BeFree,GAD | 25886314 | Detail |
<0.001 | Cirrhosis | By immunohistochemistry EGFR and TGF-α were overexpressed in HCC and cirrhotic c... | BeFree | 26279457 | Detail |
0.002 | androgen independent prostate cancer | NA | BeFree | Detail | |
0.004 | Metastatic Malignant Neoplasm to the Leptomeninges | Erlotinib combined with pemetrexed/cisplatin may be effective in the treatment o... | BeFree | 24985049 | Detail |
0.004 | Metastatic Malignant Neoplasm to the Leptomeninges | It represents a potential therapeutic option against LM after failure of standar... | BeFree | 25921002 | Detail |
0.001 | Benign Prostatic Hyperplasia | NA | BeFree | Detail | |
<0.001 | Uterine Corpus Carcinosarcoma | NA | BeFree | Detail | |
<0.001 | Intimal sarcoma | NA | BeFree | Detail | |
<0.001 | lung sarcomatoid carcinoma | NA | BeFree | Detail | |
0.002 | Non-Neoplastic Disorder | NA | BeFree | Detail | |
<0.001 | sinonasal undifferentiated carcinoma | NA | BeFree | Detail | |
<0.001 | carcinosarcoma of lung | NA | BeFree | Detail | |
0.001 | Meningioma, benign, no ICD-O subtype | NA | BeFree | Detail | |
<0.001 | Idiopathic Pulmonary Fibrosis | NA | BeFree | Detail | |
<0.001 | rippling muscle disease 1 | NA | BeFree | Detail | |
<0.001 | Familial ependymoma | NA | BeFree | Detail | |
0.001 | Myeloproliferative disorder, chronic, with eosinophilia | EGFR mutations may play an important role in the formation of MPE. | BeFree | 25239875 | Detail |
0.001 | Myeloproliferative disorder, chronic, with eosinophilia | SERS measurement based on sea-urchin-like AuNC was an efficient method for EGFR ... | BeFree | 25495142 | Detail |
0.001 | Myeloproliferative disorder, chronic, with eosinophilia | Metastatic RET-rearranged lung adenocarcinoma patients with MPE might have favor... | BeFree | 25773866 | Detail |
<0.001 | Rippling muscle disease | NA | BeFree | Detail | |
<0.001 | ALKALINE PHOSPHATASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS 1 | NA | BeFree | Detail | |
0.004 | uterine corpus cancer | These new findings about endometrial cancer suggest a potential for targeted the... | BeFree | 24820961 | Detail |
<0.001 | low grade glioma | The protein expression of PCNA and EGFR was significantly higher in high-grade t... | BeFree | 25688509 | Detail |
<0.001 | Urothelial Carcinoma | NA | BeFree | Detail | |
0.145 | liver carcinoma | This study suggests that γ-H2AX is associated with angiogenesis of HCC and γ-H2A... | BeFree,CTD_human,GAD,LHGDN | 25537504 | Detail |
0.145 | liver carcinoma | B3GNT2, a polylactosamine synthase, regulates glycosylation of EGFR in H7721 hum... | BeFree,CTD_human,GAD,LHGDN | 25605193 | Detail |
0.145 | liver carcinoma | UNC50 prompts G1/S transition and proliferation in HCC by regulation of epiderma... | BeFree,CTD_human,GAD,LHGDN | 25738771 | Detail |
0.145 | liver carcinoma | These results suggested that ECHS1 may promote cell proliferation in HCC in an E... | BeFree,CTD_human,GAD,LHGDN | 25760819 | Detail |
0.145 | liver carcinoma | Overexpression of EGFR in HCC patients can be promising in selecting those who c... | BeFree,CTD_human,GAD,LHGDN | 26279457 | Detail |
<0.001 | Triple-negative breast carcinoma | NA | BeFree | Detail | |
0.002 | Oropharyngeal Carcinoma | NA | BeFree | Detail | |
0.200 | Acute kidney injury | NA | CTD_human,RGD | Detail | |
<0.001 | Merkel Cell Polyomavirus Infection | NA | BeFree | Detail | |
<0.001 | Steatohepatitis | NA | BeFree | Detail | |
<0.001 | Promyelocytic leukemia | NA | BeFree | Detail | |
<0.001 | Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma | Expression levels of p16, β-catenin, and epidermal growth factor receptor (EGFR)... | BeFree | 25209444 | Detail |
<0.001 | Gestational trophoblastic disease | NA | BeFree | Detail | |
0.005 | Nasopharyngeal carcinoma | NA | BeFree | Detail | |
0.005 | Prostatic Hyperplasia | NA | GAD,LHGDN | Detail | |
<0.001 | Pregnancy Related Skin Change | NA | BeFree | Detail | |
<0.001 | Early-Stage Breast Carcinoma | NA | BeFree | Detail | |
<0.001 | Stage IV Colorectal Cancer AJCC v7 | Although KRAS mutation has a predictive role in stage IV colorectal cancer (CRC)... | BeFree | 24889488 | Detail |
<0.001 | Combined large cell neuroendocrine carcinoma | We assume that the LCNEC originated from the adenocarcinoma based on the fact th... | BeFree | 23518631 | Detail |
<0.001 | Serrated polyp | NA | BeFree | Detail | |
0.008 | Progressive cGVHD | Despite the efficacy and superiority of EGFR TKIs over chemotherapy as first-lin... | BeFree | 25176972 | Detail |
0.015 | Triple Negative Breast Neoplasms | Triple-negative breast cancer (TNBC) is a distinct breast cancer subtype defined... | BeFree | 24786829 | Detail |
0.015 | Triple Negative Breast Neoplasms | Mutations in exons 19 and 21 of EGFR are commonly found to be associated with no... | BeFree | 24969895 | Detail |
0.015 | Triple Negative Breast Neoplasms | In aggressive, triple-negative, basal-like breast cancers, most tumors display i... | BeFree | 25073112 | Detail |
0.015 | Triple Negative Breast Neoplasms | Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor syne... | BeFree | 25129346 | Detail |
0.015 | Triple Negative Breast Neoplasms | When TNBCs were divided into basal (cytokeratin 5/6 (CK5/6)+ and/or epidermal gr... | BeFree | 25179840 | Detail |
0.015 | Triple Negative Breast Neoplasms | We used cell line models of EGFR-positive/PTEN null TNBC to elucidate the signal... | BeFree | 25454348 | Detail |
0.015 | Triple Negative Breast Neoplasms | Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cell... | BeFree | 25501339 | Detail |
0.015 | Triple Negative Breast Neoplasms | The further determination of how the NHERF1‑EGFR interaction is regulated may im... | BeFree | 25530180 | Detail |
0.015 | Triple Negative Breast Neoplasms | The distinct expression of AR and EGFR and the prevalence of BRCA1 mutation indi... | BeFree | 25695063 | Detail |
0.015 | Triple Negative Breast Neoplasms | Triple negative breast cancer (TNBC) is a distinct breast cancer subtype, which ... | BeFree | 25748387 | Detail |
0.015 | Triple Negative Breast Neoplasms | Here, we describe how PEA-15 expression affects the dephosphorylation of epiderm... | BeFree | 25796184 | Detail |
0.015 | Triple Negative Breast Neoplasms | Neurokinin-1 activation affects EGFR related signal transduction in triple negat... | BeFree | 25817575 | Detail |
0.015 | Triple Negative Breast Neoplasms | Signaling via epidermal growth factor receptor (EGFR) and Src kinase pathways pr... | BeFree | 25823823 | Detail |
0.015 | Triple Negative Breast Neoplasms | The expression of p53 was higher in luminal B, HER2-enriched, and triple-negativ... | BeFree | 25966200 | Detail |
0.015 | Triple Negative Breast Neoplasms | EGFR is one of the best-validated driver genes for TNBC. | BeFree | 26010411 | Detail |
<0.001 | Breast cancer, lobular | Strong adverse effect of epidermal growth factor receptor 2 overexpression on pr... | BeFree | 25804795 | Detail |
<0.001 | Basal-Like Breast Carcinoma | NA | BeFree | Detail | |
<0.001 | Prostatic Cancer, Castration-Resistant | NA | BeFree | Detail | |
<0.001 | Intracranial glioma | NA | BeFree | Detail | |
0.014 | Infection | NA | LHGDN | Detail | |
0.003 | Thymus Neoplasms | NA | BeFree,LHGDN | Detail | |
0.001 | ESTROGEN RESISTANCE | NA | BeFree | Detail | |
0.002 | Experimental Organism Basal Cell Carcinoma | NA | BeFree | Detail | |
<0.001 | Tumors in children | NA | BeFree | Detail | |
0.120 | Inflammatory skin and bowel disease, neonatal, 2 | NA | UNIPROT | Detail | |
0.008 | papillary adenocarcinoma | NA | BeFree,GAD,LHGDN | Detail | |
0.002 | adenoma | Inhibition of USP8 or EGFR is promising for treating USP8-mutated corticotrophin... | BeFree | 25675982 | Detail |
<0.001 | adenosarcoma | NA | BeFree | Detail | |
<0.001 | Adenovirus Infections | NA | BeFree | Detail | |
<0.001 | adrenal gland hyperfunction | NA | BeFree | Detail | |
<0.001 | Alzheimer's disease | NA | BeFree | Detail | |
<0.001 | ameloblastoma | NA | BeFree | Detail | |
<0.001 | amyotrophic lateral sclerosis | NA | BeFree | Detail | |
0.001 | Anaplasia | NA | BeFree | Detail | |
0.002 | Anus Neoplasms | NA | GAD | Detail | |
<0.001 | arteriosclerosis | NA | BeFree | Detail | |
0.002 | rheumatoid arthritis | NA | BeFree | Detail | |
0.087 | asthma | Amphiregulin is a member of the family of epidermal growth factor receptor (EGFR... | BeFree,GAD,LHGDN,RGD | 26047642 | Detail |
0.024 | Astrocytoma | These findings provide important information on the mechanisms involved in the p... | BeFree,GAD,LHGDN | 24170555 | Detail |
<0.001 | atherosclerosis | NA | BeFree | Detail | |
0.003 | Bacterial Infections | NA | LHGDN | Detail | |
0.003 | Barrett esophagus | NA | LHGDN | Detail | |
0.120 | Bile Duct Neoplasms | NA | CTD_human | Detail | |
0.005 | Biliary Tract Neoplasm | NA | GAD | Detail | |
0.019 | Malignant neoplasm of urinary bladder | EGFR as a potential therapeutic target for a subset of muscle-invasive bladder c... | BeFree,GAD | 25009231 | Detail |
0.019 | Malignant neoplasm of urinary bladder | Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-su... | BeFree,GAD | 25405368 | Detail |
0.019 | Malignant neoplasm of urinary bladder | The epidermal growth factor receptor (EGFR) family is reportedly overexpressed i... | BeFree,GAD | 25482142 | Detail |
0.130 | Bladder Neoplasm | NA | BeFree,CTD_human,LHGDN | Detail | |
<0.001 | Bone Diseases | NA | BeFree | Detail | |
<0.001 | Bone neoplasms | NA | BeFree | Detail | |
<0.001 | borderline personality disorder | NA | BeFree | Detail | |
0.024 | Brain Neoplasms | The mechanisms that drive therapeutic resistance to EGFR inhibitors in brain tum... | BeFree,GAD,LHGDN | 25103728 | Detail |
0.024 | Brain Neoplasms | Here, human brain tumor-initiating cell (BTIC) lines with different combinations... | BeFree,GAD,LHGDN | 25316808 | Detail |
0.024 | Brain Neoplasms | Optical imaging of targeted β-galactosidase in brain tumors to detect EGFR level... | BeFree,GAD,LHGDN | 25775241 | Detail |
0.024 | Brain Neoplasms | The naturally secreted and O-GlcNAcylated MIF binds to EGFR, thereby inhibiting ... | BeFree,GAD,LHGDN | 26280537 | Detail |
0.104 | Malignant neoplasm of breast | A new class of protein cancer biomarker candidates: differentially expressed spl... | BeFree,GAD | 24802673 | Detail |
0.104 | Malignant neoplasm of breast | Complete pharmacologic EGFR/HER2 inhibition is required to reverse Src-dependent... | BeFree,GAD | 24887236 | Detail |
0.104 | Malignant neoplasm of breast | This is a revised case report of a 52 year old Caucasian female with Li-Fraumeni... | BeFree,GAD | 25047674 | Detail |
0.104 | Malignant neoplasm of breast | We suggest that TJE is a new potential reagent for EGFR-targeted therapy and ant... | BeFree,GAD | 25051266 | Detail |
0.104 | Malignant neoplasm of breast | The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will be r... | BeFree,GAD | 25051360 | Detail |
0.104 | Malignant neoplasm of breast | The epidermal growth factor receptor (EGFR) is a member of the ErbB family that ... | BeFree,GAD | 25140053 | Detail |
0.104 | Malignant neoplasm of breast | Here, we report a proof-of-concept experiment demonstrating that small peptides ... | BeFree,GAD | 25220456 | Detail |
0.104 | Malignant neoplasm of breast | Our results showed that CD44 expression was significantly increased by epidermal... | BeFree,GAD | 25269647 | Detail |
0.104 | Malignant neoplasm of breast | Prognostic and predictive values of EGFR overexpression and EGFR copy number alt... | BeFree,GAD | 25349977 | Detail |
0.104 | Malignant neoplasm of breast | In both the primary cancers and the metastases, Claudin-4 was most frequently ex... | BeFree,GAD | 25417118 | Detail |
0.104 | Malignant neoplasm of breast | BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human ... | BeFree,GAD | 25417703 | Detail |
0.104 | Malignant neoplasm of breast | Because mutations within HER1/EGFR are predictive of response to tyrosine kinase... | BeFree,GAD | 25435280 | Detail |
0.104 | Malignant neoplasm of breast | Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast c... | BeFree,GAD | 25454348 | Detail |
0.104 | Malignant neoplasm of breast | Coexpression of EGFR and HER2 has been associated with poor disease outcome, hig... | BeFree,GAD | 25510900 | Detail |
0.104 | Malignant neoplasm of breast | While ERBB1, ERBB2 and ERBB3 are often overexpressed or activated in breast canc... | BeFree,GAD | 25516216 | Detail |
0.104 | Malignant neoplasm of breast | We propose that miR-7 regulated pathways, including EGFR and Src kinase, represe... | BeFree,GAD | 25532106 | Detail |
0.104 | Malignant neoplasm of breast | Estrogen-responsive genes most significantly influenced by cohesin were enriched... | BeFree,GAD | 25542856 | Detail |
0.104 | Malignant neoplasm of breast | This study identifies mutant p53 as an essential player in ErbB2 and EGFR-mediat... | BeFree,GAD | 25573952 | Detail |
0.104 | Malignant neoplasm of breast | TXNIP interaction with the Her-1/2 pathway contributes to overall survival in br... | BeFree,GAD | 25605021 | Detail |
0.104 | Malignant neoplasm of breast | Lapatinib, a dual tyrosine kinase inhibitor that interrupts the epidermal growth... | BeFree,GAD | 25605188 | Detail |
0.104 | Malignant neoplasm of breast | Amplified HER2, which encodes a member of the epidermal growth factor receptor (... | BeFree,GAD | 25605973 | Detail |
0.104 | Malignant neoplasm of breast | Further understanding of the paradoxical function of EGFR between primary and me... | BeFree,GAD | 25622905 | Detail |
0.104 | Malignant neoplasm of breast | Loss of catalytically functional PTPN14 increased the secretion of growth factor... | BeFree,GAD | 25690013 | Detail |
0.104 | Malignant neoplasm of breast | More and more evidences demonstrate that androgen receptor (AR), epidermal growt... | BeFree,GAD | 25695063 | Detail |
0.104 | Malignant neoplasm of breast | Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluore... | BeFree,GAD | 25702787 | Detail |
0.104 | Malignant neoplasm of breast | A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 ac... | BeFree,GAD | 25766325 | Detail |
0.104 | Malignant neoplasm of breast | To identify a prognostic signature for breast cancer, we performed DNA methylati... | BeFree,GAD | 25773928 | Detail |
0.104 | Malignant neoplasm of breast | Kindlin-2 interacts with and stabilizes EGFR and is required for EGF-induced bre... | BeFree,GAD | 25790908 | Detail |
0.104 | Malignant neoplasm of breast | Upregulation of HER3 has been found to be a major mechanism underlying drug resi... | BeFree,GAD | 25849870 | Detail |
0.104 | Malignant neoplasm of breast | Endocrine therapy considerations in postmenopausal patients with hormone recepto... | BeFree,GAD | 25857348 | Detail |
0.104 | Malignant neoplasm of breast | Correlation between p53 and epidermal growth factor receptor expression in breas... | BeFree,GAD | 25966200 | Detail |
0.104 | Malignant neoplasm of breast | Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investig... | BeFree,GAD | 25969993 | Detail |
0.104 | Malignant neoplasm of breast | Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced act... | BeFree,GAD | 26006730 | Detail |
0.104 | Malignant neoplasm of breast | The majority of breast cancers present with estrogen receptor (ER)-positive and ... | BeFree,GAD | 26059247 | Detail |
0.104 | Malignant neoplasm of breast | Thirty-two locally/systemically advanced breast cancers treated with first-line ... | BeFree,GAD | 26178788 | Detail |
0.003 | Breast Diseases | NA | LHGDN | Detail | |
<0.001 | bronchitis | NA | BeFree | Detail | |
<0.001 | bronchopulmonary dysplasia | NA | BeFree | Detail | |
<0.001 | Cachexia | NA | BeFree | Detail | |
0.004 | Carcinoid Tumor | NA | BeFree,LHGDN | Detail | |
0.023 | Malignant tumor of colon | Here we show a clear correlation between the efficacy of anti-EGFR inhibitors wi... | BeFree | 24556630 | Detail |
0.023 | Malignant tumor of colon | These results indicate that ERBB3 is a potential target for EGFR- and ERBB2-resi... | BeFree | 24970817 | Detail |
0.023 | Malignant tumor of colon | Importantly, hyperactivation of SRC/EGFR signaling triggered by loss of PTPRO le... | BeFree | 25301722 | Detail |
0.023 | Malignant tumor of colon | EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon ... | BeFree | 25535899 | Detail |
0.023 | Malignant tumor of colon | KRAS mutations also induce anti-EGFR antibody resistance in adenocarcinoma such ... | BeFree | 25589625 | Detail |
0.023 | Malignant tumor of colon | Mutations at the K-RAS locus in colon cancer cells are frequently associated wit... | BeFree | 25675084 | Detail |
0.023 | Malignant tumor of colon | In contrast, forced expression of MITF in melanoma and colon cancer cells inhibi... | BeFree | 25789707 | Detail |
0.004 | Malignant neoplasm of endometrium | These new findings about endometrial cancer suggest a potential for targeted the... | BeFree | 24820961 | Detail |
0.002 | Malignant neoplasm of larynx | Higher expression of the EGFR cascade in cannabis smokers revealed that cannabis... | BeFree | 25736926 | Detail |
<0.001 | Adenocarcinoma of prostate | Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic... | BeFree | 26299074 | Detail |
0.006 | Rectal Carcinoma | EGFR ligands and DNA repair genes: genomic predictors of complete response after... | BeFree,GAD | 25026457 | Detail |
<0.001 | Malignant neoplasm of skin | NA | BeFree | Detail | |
0.003 | Malignant neoplasm of thyroid | NA | BeFree | Detail | |
0.003 | basal cell carcinoma | NA | LHGDN | Detail | |
0.027 | Bronchioloalveolar Adenocarcinoma | We assume that the LCNEC originated from the adenocarcinoma based on the fact th... | BeFree,GAD,LHGDN | 23518631 | Detail |
0.027 | Bronchioloalveolar Adenocarcinoma | A significantly higher incidence of EGFR mutations was observed in bronchioloalv... | BeFree,GAD,LHGDN | 25684509 | Detail |
<0.001 | Bronchogenic Carcinoma | NA | BeFree | Detail | |
0.008 | Noninfiltrating Intraductal Carcinoma | NA | BeFree,LHGDN | Detail | |
<0.001 | Merkel cell carcinoma | NA | BeFree | Detail | |
0.005 | mucinous adenocarcinoma | A single-institute cohort study in Taiwan was performed to determine the mutatio... | BeFree,GAD | 24913807 | Detail |
0.005 | mucinous adenocarcinoma | The clinicopathological significance of ALK rearrangements and KRAS and EGFR mut... | BeFree,GAD | 25813151 | Detail |
0.005 | mucinous adenocarcinoma | The aim of this study was to compare colorectal adenocarcinoma with mucinous com... | BeFree,GAD | 25907382 | Detail |
0.002 | Carcinoma, Papillary | NA | GAD | Detail | |
0.016 | renal cell carcinoma | NA | BeFree,GAD,LHGDN | Detail |
Annotation
Annotations
Descrption | Source | Links |
---|---|---|
A phase 2 study of 120 stage IIIB-IV lung adenocarcinoma patients reported improved progression free... | CIViC Evidence | Detail |
The phase 3 (EURTAC) study consisted of of 173 non-small cell lung cancer patients who had not had p... | CIViC Evidence | Detail |
In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutati... | CIViC Evidence | Detail |
In a cohort of NSCLC patients treated with tyrosine kinase inhibitors erlotinib or gefitinib, 61 pat... | CIViC Evidence | Detail |
In a study of 1261 non-small cell lung cancer patients, 49.8% of the analyzed tumors had EGFR mutati... | CIViC Evidence | Detail |
In a cohort of NSCLC patients tested for mutation in EGFR exons 18-21 a subset had uncommon mutation... | CIViC Evidence | Detail |
In a study of 19 non-small cell lung carcinoma patients with EGFR exon 20 insertion mutation and tre... | CIViC Evidence | Detail |
In a non-small cell lung cancer patient harboring EGFR P772_H773insYNP mutation, EGFR P772_H773insYN... | CIViC Evidence | Detail |
In a lung adenocarcinoma patient harboring EGFR P772_V774insPHV mutation, EGFR P772_V774insPHV was a... | CIViC Evidence | Detail |
Detection of mutation-specific epidermal growth factor receptor (E746-A750del) and lack of detection... | DisGeNET | Detail |
Lack of mutations in protein tyrosine kinase domain coding exons 19 and 21 of the EGFR gene in oral ... | DisGeNET | Detail |
Over-expression of epidermal growth factor receptor (EGFR) has been identified as a common feature a... | DisGeNET | Detail |
Our results suggest that EGFR expression in squamous cell carcinoma is different with regard to tumo... | DisGeNET | Detail |
Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is ... | DisGeNET | Detail |
Our data show that the overall frequency of EGFR gene mutations in lung adenocarcinomas in the East ... | DisGeNET | Detail |
The occurrence of EGFR mutations in pulmonary SQCC might be overestimated. | DisGeNET | Detail |
Shikonin causes cell-cycle arrest and induces apoptosis by regulating the EGFR-NF-κB signalling path... | DisGeNET | Detail |
Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and... | DisGeNET | Detail |
High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted... | DisGeNET | Detail |
This study details the empirical basis for a feasible clinical solution for squamous cell carcinomas... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Studies in cervical cancer indicate that E5 increases epidermal growth factor receptor (EGFR) recycl... | DisGeNET | Detail |
FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We find that miR-34a inversely correlates with MET expression and miR-608 inversely correlates with ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Three different macroscopic subtypes of colorectal neoplasms display distinct carcinogenetic pathway... | DisGeNET | Detail |
We exploited circulating tumor DNA (ctDNA) to genotype colorectal tumors and track clonal evolution ... | DisGeNET | Detail |
We validated COLD-ddPCR on multiple mutations in TP53 and in EGFR using serial mutation dilutions an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Taken together, this study defines the genomic landscape underlying phyllodes tumor development, sug... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Staphylococcus aureus skin colonization is universal in atopic dermatitis and common in cancer patie... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The 13 patients with DM were more likely to express IGF-1R (p=0.001) and had shorter PFS times when ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In addition, EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting... | DisGeNET | Detail |
NA | DisGeNET | Detail |
IL-6, IL-9, CCL24, CCL18, IL-10, IFN-γ, and CCL2 were highly increased (>6-fold); 26 genes were mode... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Staphylococcus aureus skin colonization is universal in atopic dermatitis and common in cancer patie... | DisGeNET | Detail |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown improved progre... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We show for the first time a significant treatment response to the EGFR tyrosine kinase inhibitor ge... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
IL-6, IL-9, CCL24, CCL18, IL-10, IFN-γ, and CCL2 were highly increased (>6-fold); 26 genes were mode... | DisGeNET | Detail |
Epidermal growth factor receptor (EGFR), HER2 and insulin-like growth factor-1 receptor (IGF-1R) sta... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Interferon-α inducible protein 6 impairs EGFR activation by CD81 and inhibits hepatitis C virus infe... | DisGeNET | Detail |
Hepatitis C virus NS5A protein blocks epidermal growth factor receptor degradation via a proline mot... | DisGeNET | Detail |
Impact of epidermal growth factor receptor and transforming growth factor-α on hepatitis C virus-ind... | DisGeNET | Detail |
To address the concern that this safety feature may reduce oncolytic activity, we inserted the miR-1... | DisGeNET | Detail |
A multi-institutional study of clinicopathological features and molecular epidemiology of epidermal ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Diagnostic values of vascular endothelial growth factor and epidermal growth factor receptor for ben... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A common germline deletion in the BIM gene was recently shown to favor the production of non-apoptot... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
By immunohistochemistry EGFR and TGF-α were overexpressed in HCC and cirrhotic cases compared to CHC... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
MiR-133a expression was negatively correlated to lymphatic metastasis (r = -0.182, P = 0.042), tumor... | DisGeNET | Detail |
The initial set of trials will focus on different questions: (1) Exceptional Responders Initiative-w... | DisGeNET | Detail |
Consistent with previous studies demonstrating a role for muscarinic and epidermal growth factor rec... | DisGeNET | Detail |
The present study was to determine the role of KRAS status in EGFR antibody treatment for gastric ca... | DisGeNET | Detail |
Many molecular pathways are currently under investigation as therapeutic targets in gastric cancer, ... | DisGeNET | Detail |
These results support the involvement of EGFR and HER2 in gastric cancer and suggest an interesting ... | DisGeNET | Detail |
Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via ... | DisGeNET | Detail |
Identification of EGFR expression status association with metastatic lymph node density (ND) by expr... | DisGeNET | Detail |
Patients with HER2(+) /EGFR(+) /MET(+) GCs had a substantial risk of death with a hazard ratio of 3.... | DisGeNET | Detail |
Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. | DisGeNET | Detail |
Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena pro... | DisGeNET | Detail |
The prevalence of genomic copy number aberrations of epidermal growth factor receptor (EGFR), human ... | DisGeNET | Detail |
In addition, synergy in growth inhibition was observed when the GC cells were treated with a combina... | DisGeNET | Detail |
The results demonstrated that EGFR phosphorylation was markedly inhibited in gastric cancer cell lin... | DisGeNET | Detail |
Cetuximab, an immunoglobulin G1 chimeric monoclonal antibody directed against the epidermal growth f... | DisGeNET | Detail |
EGFR gene polymorphisms -216G>T and -191C>A are risk markers for gastric cancer in Mexican populatio... | DisGeNET | Detail |
In gastric cancer (GC), epidermal growth factor receptor (EGFR) overexpression associates with poor ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Higher expression of the EGFR cascade in cannabis smokers revealed that cannabis smoking may be a ma... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overexpression of EGFR predicts poor outcomes of MBs, small cell GBMs and PNETs, suggesting those th... | DisGeNET | Detail |
Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. | DisGeNET | Detail |
An inverse relationship between MITF, vemurafenib resistance, and EGFR was then observed in patient ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Regarding that also EGFR amplifications in MPM are absolute rarities, our findings may be a hint tha... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway. | DisGeNET | Detail |
The germline polymorphisms studied were thymidylate synthase, (VNTR/5'UTR, 2R G>C single nucleoti... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Association of PTPN22 rs2476601 and EGFR rs17337023 Gene polymorphisms and rheumatoid arthritis in Z... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Using the Snapshot assay, mutation statuses were detected for EGFR, Kirsten rate sarcoma viral oncog... | DisGeNET | Detail |
Clinically, EGFR inhibitors are ineffective as single agent compounds in patients with recurrent NB,... | DisGeNET | Detail |
Transgenic mice heterozygous for a Trp53-null allele and overexpressing EGFR in Schwann cells had a ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
For overall patients, EGFR mutation status was associated with gender, pStage, pT status, lepidic do... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Thus, miR-143, EGFR, and MMP9 are therapeutic targets for inhibiting OS invasion. | DisGeNET | Detail |
NA | DisGeNET | Detail |
Yes-associated protein (YAP) has been reported to be associated with the prognosis of various cancer... | DisGeNET | Detail |
The crosstalk between PAFR and EGFR suggests a potentially important signaling linkage between infla... | DisGeNET | Detail |
miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL an... | DisGeNET | Detail |
We found that ErbB-1 was localized predominantly in the nucleus of ovarian cancer cells examined, co... | DisGeNET | Detail |
Of the two postulated miR-7 target genes we examined, BCL2, but not EGFR, seems to be a possible miR... | DisGeNET | Detail |
Both epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor 1 (FGFR1) are ove... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
EGFR mutations were not identified in exophytic or oncocytic papillomas or non-ISP-associated SNSCC,... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
It is feasible to detect the gene copy number of the pleural effusion cell mass EGFR by FISH techniq... | DisGeNET | Detail |
The results established the important role of HRM as a reliable and efficient method to determine EG... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
However, the results of phase II trials of EGFR inhibitors-as well as other targeted agents--in sali... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Does gefitinib have effects on EGFR mutation-positive thymoma? -Case report of thymoma recurrence. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung... | DisGeNET | Detail |
Comparing to male with pulmonary TB history, female with or without pulmonary TB history and male wi... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Some miR-7 targets, including B-cell lymphoma 2 (BCL2) and epidermal growth factor receptor (EGFR), ... | DisGeNET | Detail |
Frequency of EGFR mutations in lung adenocarcinoma with malignant pleural effusion: Implication of c... | DisGeNET | Detail |
Sea-urchin-like Au nanocluster with surface-enhanced raman scattering in detecting epidermal growth ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
EGFR-mutated lung cancer in Li-Fraumeni syndrome. | DisGeNET | Detail |
We report two cases of non-smoker patients diagnosed with EGFR-mutated lung adenocarcinoma and beari... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Finally, an inverse correlation was observed between Fhit and phospho-EGFR levels in a cohort of hum... | DisGeNET | Detail |
The initial set of trials will focus on different questions: (1) Exceptional Responders Initiative-w... | DisGeNET | Detail |
Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squam... | DisGeNET | Detail |
We examined EGFR mutations in exons 19 and 21 in 147 NSCLC patients (excluding squamous cell lung ca... | DisGeNET | Detail |
Cell membrane CD44v6 levels in squamous cell carcinoma of the lung: association with high cellular p... | DisGeNET | Detail |
Epidermal growth factor receptor gene mutation status in pure squamous-cell lung cancer in Chinese p... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Epigenetic changes of EGFR have an important role in BRAF inhibitor-resistant cutaneous melanomas. | DisGeNET | Detail |
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib. | DisGeNET | Detail |
Inhibition of EGFR in pre-clinical models of oral pre-malignancies validates this approach as an eff... | DisGeNET | Detail |
Targeting Ley on EGFR could have a potential therapeutic effect on oral cancer. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Anecdotal benefit from EGFR-targeted therapy has been reported in anal cancer and a negative correla... | DisGeNET | Detail |
In conclusion, the present study indicated that the mechanism of action of miR-146b-5p in GBC involv... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study, we analyzed the expression of MAGE-A, a cancer-testis antigen, in tumors from a cohor... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In multivariate analysis, lobulated margins (odds ratio, 4.815; 95% confidence interval [CI]: 1.789,... | DisGeNET | Detail |
Our findings support a model in which nuclear EGFR acts as a transcriptional repressor to constrain ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Aberrant epidermal growth factor receptor (EGFR) signaling in non-small cell lung cancer (NSCLC) is ... | DisGeNET | Detail |
ERBB2/HER2 belongs to the EGFR-family of receptor tyrosine kinases and its overexpression can promot... | DisGeNET | Detail |
One mechanism by which EGFR promotes tumor progression is by activating signal cascades that lead to... | DisGeNET | Detail |
Epidermal growth factor receptor (EGFR) mutation is one of the hallmarks of cancer progression and r... | DisGeNET | Detail |
Activation of epidermal growth factor receptor (EGFR), which occurs in many types of tumour, promote... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Epidermal growth factor receptor (EGFR) pathway genes and interstitial lung disease: an association ... | DisGeNET | Detail |
The frequency of interstitial lung disease (ILD) of grade ≥3 was low (0.6-2.2%) with all three EGFR-... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overexpression of EGFR predicts poor outcomes of MBs, small cell GBMs and PNETs, suggesting those th... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We identified 126 EGFR-mutated (21.8% of 578 successful genotyped cases) lung cancers and only 2 (1.... | DisGeNET | Detail |
In this review article, we discuss the molecular aspects of CCA including the role of erbB receptor ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A significantly higher incidence of EGFR mutations was observed in bronchioloalveolar carcinomas (28... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Transgenic mice heterozygous for a Trp53-null allele and overexpressing EGFR in Schwann cells had a ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Inhibition of EGFR in pre-clinical models of oral pre-malignancies validates this approach as an eff... | DisGeNET | Detail |
Targeting Ley on EGFR could have a potential therapeutic effect on oral cancer. | DisGeNET | Detail |
Our case suggests that dual targeting of epidermal growth factor receptor (EGFR) by a combination of... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
It represents a potential therapeutic option against LM after failure of standard-dose EGFR-TKIs, es... | DisGeNET | Detail |
ALK positive lung adenocarcinomas are more likely than EGFR mutant lung adenocarcinomas to be associ... | DisGeNET | Detail |
In conclusion, the present study indicated that the mechanism of action of miR-146b-5p in GBC involv... | DisGeNET | Detail |
EGFR has been implicated in various malignancies such as NSCLC, breast, head and neck, and pancreati... | DisGeNET | Detail |
Together, these studies provide further support for a role for EGFR and HER2 in pancreatic cancer pr... | DisGeNET | Detail |
Lumican plays a restrictive role in EGFR-expressing pancreatic cancer progression. | DisGeNET | Detail |
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and... | DisGeNET | Detail |
In conclusion, our studies will enhance the translational acquaintance of pan-EGFR inhibitors for co... | DisGeNET | Detail |
Moreover, EGFR was found to mediate the REG3A signal for PaC cell growth and JAK2/STAT3 activation, ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Targeting c-Kit plus HER1 or AXL/c-Met abrogates IM resistance in GIST. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Localisation of PTPD1 at the plasma membrane was mediated by its FERM domain and enabled the formati... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In conclusion, miR-214 appears to participate in the development of hepatic fibrosis by modulating t... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Epidermal growth factor receptor overexpression is a predictive factor for trastuzumab response in H... | DisGeNET | Detail |
Resistance to the human epidermal growth factor receptor (HER2)-targeted antibody trastuzumab is a m... | DisGeNET | Detail |
The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
To determine the frequency and clinical significance of epidermal growth factor receptor (EGFR) muta... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Chromosome 7 polysomy may be responsible for EGFR gene amplifications, and we concluded that MET and... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Thus, we suggest that Musashi-1, Lgr5, and pEGFR are overexpressed in human SIAs and may play roles ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
An inverse relationship between MITF, vemurafenib resistance, and EGFR was then observed in patient ... | DisGeNET | Detail |
Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. | DisGeNET | Detail |
Better anti-EGFR treatment efficacy was related to lower EGFR expression in head and neck cancer cel... | DisGeNET | Detail |
Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models bu... | DisGeNET | Detail |
Effective therapeutic approach for head and neck cancer by an engineered minibody targeting the EGFR... | DisGeNET | Detail |
MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhib... | DisGeNET | Detail |
The EGFR-targeted antibody cetuximab is effective against head and neck cancer (HNSCC), but in only ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
EGFR gene mutations in patients with adenosquamous lung carcinoma. | DisGeNET | Detail |
We show for the first time a significant treatment response to the EGFR tyrosine kinase inhibitor ge... | DisGeNET | Detail |
Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal ad... | DisGeNET | Detail |
Anecdotal benefit from EGFR-targeted therapy has been reported in anal cancer and a negative correla... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overexpression of EGFR predicts poor outcomes of MBs, small cell GBMs and PNETs, suggesting those th... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The initial set of trials will focus on different questions: (1) Exceptional Responders Initiative-w... | DisGeNET | Detail |
Preclinical studies have shown synergism between epidermal growth factor receptor (EGFR) tyrosine ki... | DisGeNET | Detail |
Cetuximab (anti-epidermal growth factor receptor - EGFR - monoclonal antibody) is a promising target... | DisGeNET | Detail |
Ubiquitous overexpression of wild type EGFR in many solid tumors has led to the development of EGFR ... | DisGeNET | Detail |
Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, sta... | DisGeNET | Detail |
Molecular testing for epidermal growth factor receptor (EGFR) mutations is required to select the mo... | DisGeNET | Detail |
Although surgical resection remains standard treatment for early stage non-small-cell lung cancer (N... | DisGeNET | Detail |
Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer... | DisGeNET | Detail |
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer har... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Biopsy specimens of patients with glottic squamous cell carcinoma and simple hyperplasia (control sa... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Studies in cervical cancer indicate that E5 increases epidermal growth factor receptor (EGFR) recycl... | DisGeNET | Detail |
FTS is responsible for radiation-induced nuclear phosphorylation of EGFR and repair of DNA damage in... | DisGeNET | Detail |
IL-6, IL-9, CCL24, CCL18, IL-10, IFN-γ, and CCL2 were highly increased (>6-fold); 26 genes were mode... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
High-Frequency Targetable EGFR Mutations in Sinonasal Squamous Cell Carcinomas Arising from Inverted... | DisGeNET | Detail |
Adenocarcinoma in situ showed significantly higher DPD mRNA levels and more EGFR mutation frequency ... | DisGeNET | Detail |
The remaining 26 quadruple-negative tumors were significantly associated with AAH/AIS (P < 0.01) and... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
FLC overexpresses EGFR in comparison to hepatocellular cancer, suggesting that EGFR targeting may be... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
EGFR has been implicated in various malignancies such as NSCLC, breast, head and neck, and pancreati... | DisGeNET | Detail |
Together, these studies provide further support for a role for EGFR and HER2 in pancreatic cancer pr... | DisGeNET | Detail |
Lumican plays a restrictive role in EGFR-expressing pancreatic cancer progression. | DisGeNET | Detail |
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and... | DisGeNET | Detail |
In conclusion, our studies will enhance the translational acquaintance of pan-EGFR inhibitors for co... | DisGeNET | Detail |
Moreover, EGFR was found to mediate the REG3A signal for PaC cell growth and JAK2/STAT3 activation, ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Female gender, tumor size, lymphovascular invasion and EGFR overexpression were predictive risk fact... | DisGeNET | Detail |
These results suggested that ADAM10 is important in regulating the proliferation, invasion and migra... | DisGeNET | Detail |
Helicobacter pylori transactivates the epidermal growth factor receptor (EGFR) on gastric epithelial... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Recently, ETS-related gene (ERG) gene rearrangements, phosphatase tensin homologue (PTEN) deletions ... | DisGeNET | Detail |
EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dep... | DisGeNET | Detail |
Human epidermal growth factor receptor family members (HER) such as EGFR and HER2 are involved in mi... | DisGeNET | Detail |
We propose that the loss of miR-203 is a molecular link in the progression of prostate cancer metast... | DisGeNET | Detail |
Among these modules, transcription Androgen Receptor (AR) nuclear signaling and Epidermal Growth Fac... | DisGeNET | Detail |
Berberine targets epidermal growth factor receptor signaling to suppress prostate cancer proliferati... | DisGeNET | Detail |
In this manuscript, we will discuss an inducible EGFR model (v-ERB-B:ER) and its effects on cell gro... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Evidence for different expression profiles for c-Met, EGFR, PTEN and the mTOR pathway in low and hig... | DisGeNET | Detail |
These new findings about endometrial cancer suggest a potential for targeted therapy with lapatinib,... | DisGeNET | Detail |
A 33-year-old pregnant mother exhibited a disseminated EGFR-mutated lung carcinoma with respiratory ... | DisGeNET | Detail |
Patients with an EGFR mutation were more prone to having synchronous LM than patients with EGFR wild... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Because STAT signaling is commonly activated in malignant gliomas as a result of constitutive EGFR a... | DisGeNET | Detail |
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Depend... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Additionally, cholangiocytes from LPS-treated mouse livers and human primary sclerosing cholangitis ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Thus, miR-143, EGFR, and MMP9 are therapeutic targets for inhibiting OS invasion. | DisGeNET | Detail |
Higher expression of the EGFR cascade in cannabis smokers revealed that cannabis smoking may be a ma... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Recently, ETS-related gene (ERG) gene rearrangements, phosphatase tensin homologue (PTEN) deletions ... | DisGeNET | Detail |
EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dep... | DisGeNET | Detail |
Human epidermal growth factor receptor family members (HER) such as EGFR and HER2 are involved in mi... | DisGeNET | Detail |
We propose that the loss of miR-203 is a molecular link in the progression of prostate cancer metast... | DisGeNET | Detail |
Among these modules, transcription Androgen Receptor (AR) nuclear signaling and Epidermal Growth Fac... | DisGeNET | Detail |
Berberine targets epidermal growth factor receptor signaling to suppress prostate cancer proliferati... | DisGeNET | Detail |
In this manuscript, we will discuss an inducible EGFR model (v-ERB-B:ER) and its effects on cell gro... | DisGeNET | Detail |
NA | DisGeNET | Detail |
miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Despite the efficacy and superiority of EGFR TKIs over chemotherapy as first-line therapy, all patie... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Although KRAS mutation has a predictive role in stage IV colorectal cancer (CRC) patients treated wi... | DisGeNET | Detail |
NA | DisGeNET | Detail |
A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB... | DisGeNET | Detail |
Complete pharmacologic EGFR/HER2 inhibition is required to reverse Src-dependent resistance to lapat... | DisGeNET | Detail |
This is a revised case report of a 52 year old Caucasian female with Li-Fraumeni syndrome with a rar... | DisGeNET | Detail |
We suggest that TJE is a new potential reagent for EGFR-targeted therapy and anti-abnormal metastasi... | DisGeNET | Detail |
The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will be reviewed in associati... | DisGeNET | Detail |
The epidermal growth factor receptor (EGFR) is a member of the ErbB family that can promote the migr... | DisGeNET | Detail |
Here, we report a proof-of-concept experiment demonstrating that small peptides interfering with the... | DisGeNET | Detail |
Our results showed that CD44 expression was significantly increased by epidermal growth factor recep... | DisGeNET | Detail |
Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-posi... | DisGeNET | Detail |
In both the primary cancers and the metastases, Claudin-4 was most frequently expressed, followed by... | DisGeNET | Detail |
BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells ... | DisGeNET | Detail |
Because mutations within HER1/EGFR are predictive of response to tyrosine kinase inhibitors (TKI) in... | DisGeNET | Detail |
Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer. | DisGeNET | Detail |
Coexpression of EGFR and HER2 has been associated with poor disease outcome, high rates of metastasi... | DisGeNET | Detail |
While ERBB1, ERBB2 and ERBB3 are often overexpressed or activated in breast cancer, and are oncogeni... | DisGeNET | Detail |
We propose that miR-7 regulated pathways, including EGFR and Src kinase, represent targets for the t... | DisGeNET | Detail |
Estrogen-responsive genes most significantly influenced by cohesin were enriched in pathways associa... | DisGeNET | Detail |
This study identifies mutant p53 as an essential player in ErbB2 and EGFR-mediated mammary tumorigen... | DisGeNET | Detail |
TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer. | DisGeNET | Detail |
Lapatinib, a dual tyrosine kinase inhibitor that interrupts the epidermal growth factor receptor (EG... | DisGeNET | Detail |
Amplified HER2, which encodes a member of the epidermal growth factor receptor (EGFR) family, is a t... | DisGeNET | Detail |
Further understanding of the paradoxical function of EGFR between primary and metastatic tumors will... | DisGeNET | Detail |
Loss of catalytically functional PTPN14 increased the secretion of growth factors and cytokines, suc... | DisGeNET | Detail |
More and more evidences demonstrate that androgen receptor (AR), epidermal growth factor receptor (E... | DisGeNET | Detail |
Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybri... | DisGeNET | Detail |
A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulat... | DisGeNET | Detail |
To identify a prognostic signature for breast cancer, we performed DNA methylation profiling and ide... | DisGeNET | Detail |
Kindlin-2 interacts with and stabilizes EGFR and is required for EGF-induced breast cancer cell migr... | DisGeNET | Detail |
Upregulation of HER3 has been found to be a major mechanism underlying drug resistance to EGFR and H... | DisGeNET | Detail |
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human ep... | DisGeNET | Detail |
Correlation between p53 and epidermal growth factor receptor expression in breast cancer classificat... | DisGeNET | Detail |
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Ac... | DisGeNET | Detail |
Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK ... | DisGeNET | Detail |
The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal grow... | DisGeNET | Detail |
Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/... | DisGeNET | Detail |
Overexpression of EGFR predicts poor outcomes of MBs, small cell GBMs and PNETs, suggesting those th... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Afatinib may therefore be an effective treatment for heavily pretreated patients with EGFR-mutated o... | DisGeNET | Detail |
Moreover, the expression of miR-183-3p in tumor tissue was found to be associated with lymph node me... | DisGeNET | Detail |
The overall analysis showed that higher expression of ALDH1A1 is associated with larger tumor size, ... | DisGeNET | Detail |
Upregulation of EGFR expression is associated with lymph node metastases of GC, and blockade of EGFR... | DisGeNET | Detail |
Female gender, tumor size, lymphovascular invasion and EGFR overexpression were predictive risk fact... | DisGeNET | Detail |
Both Univariate (U) and COX multivariate (C) analyses revealed that high EGFR and AKT1 gene copy num... | DisGeNET | Detail |
The COX-2(+)/EGFR(+) group was associated with tumor size (p=0.002), mitotic index (p=0.019), histol... | DisGeNET | Detail |
TNBC had a lower lymph node metastasis rate but higher CK5/6 and EGFR expression than the other thre... | DisGeNET | Detail |
Here we show a clear correlation between the efficacy of anti-EGFR inhibitors with their ability to ... | DisGeNET | Detail |
These results indicate that ERBB3 is a potential target for EGFR- and ERBB2-resistant colon cancer t... | DisGeNET | Detail |
Importantly, hyperactivation of SRC/EGFR signaling triggered by loss of PTPRO leads to high resistan... | DisGeNET | Detail |
To elucidate the role of HMGA1 proteins in chemoresistance we analyzed resistance to conventional dr... | DisGeNET | Detail |
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. | DisGeNET | Detail |
KRAS mutations also induce anti-EGFR antibody resistance in adenocarcinoma such as colon cancer. | DisGeNET | Detail |
Mutations at the K-RAS locus in colon cancer cells are frequently associated with lack of responsive... | DisGeNET | Detail |
In contrast, forced expression of MITF in melanoma and colon cancer cells inhibited EGFR and conferr... | DisGeNET | Detail |
Treatment of metastatic colon carcinoma with the anti-epidermal growth factor receptor antibody cetu... | DisGeNET | Detail |
The present study was to determine the role of KRAS status in EGFR antibody treatment for gastric ca... | DisGeNET | Detail |
Many molecular pathways are currently under investigation as therapeutic targets in gastric cancer, ... | DisGeNET | Detail |
These results support the involvement of EGFR and HER2 in gastric cancer and suggest an interesting ... | DisGeNET | Detail |
Inhibition of epidermal growth factor receptor signaling prohibits metastasis of gastric cancer via ... | DisGeNET | Detail |
Identification of EGFR expression status association with metastatic lymph node density (ND) by expr... | DisGeNET | Detail |
Patients with HER2(+) /EGFR(+) /MET(+) GCs had a substantial risk of death with a hazard ratio of 3.... | DisGeNET | Detail |
Knockdown of EGFR inhibits growth and invasion of gastric cancer cells. | DisGeNET | Detail |
Gastric cancer in young vs old Romanian patients: immunoprofile with emphasis on maspin and mena pro... | DisGeNET | Detail |
The prevalence of genomic copy number aberrations of epidermal growth factor receptor (EGFR), human ... | DisGeNET | Detail |
In addition, synergy in growth inhibition was observed when the GC cells were treated with a combina... | DisGeNET | Detail |
The results demonstrated that EGFR phosphorylation was markedly inhibited in gastric cancer cell lin... | DisGeNET | Detail |
Cetuximab, an immunoglobulin G1 chimeric monoclonal antibody directed against the epidermal growth f... | DisGeNET | Detail |
EGFR gene polymorphisms -216G>T and -191C>A are risk markers for gastric cancer in Mexican populatio... | DisGeNET | Detail |
In gastric cancer (GC), epidermal growth factor receptor (EGFR) overexpression associates with poor ... | DisGeNET | Detail |
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a ... | DisGeNET | Detail |
Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-2... | DisGeNET | Detail |
The epidermal growth factor receptor (EGFR) family is reportedly overexpressed in bladder cancer, an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Using the Snapshot assay, mutation statuses were detected for EGFR, Kirsten rate sarcoma viral oncog... | DisGeNET | Detail |
Clinically, EGFR inhibitors are ineffective as single agent compounds in patients with recurrent NB,... | DisGeNET | Detail |
To show additional prognostic information about the mutational profile and new International Associa... | DisGeNET | Detail |
A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patien... | DisGeNET | Detail |
The aim of the present study was to examine EGFR on protein level, confronting cellular pattern of e... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Lung and renal cancer, two areas in which huge progress has been made in the last decade, will be us... | DisGeNET | Detail |
Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGF... | DisGeNET | Detail |
NA | DisGeNET | Detail |
The epidermal growth factor receptor critically regulates endometrial function during early pregnanc... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
TCDC also increased the expression of epidermal growth factor receptor (EGFR) ligands and TACE activ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomy... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Transgenic mice heterozygous for a Trp53-null allele and overexpressing EGFR in Schwann cells had a ... | DisGeNET | Detail |
Next, the identification of less EGFR mutations in the EGFR gene of the pleural mesothelioma an up t... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
RTK expression (c-Kit, c-Met, AXL, HER-1, HER-2, IGF-1R) in pre-/post-imatinib (IM) GIST patient sam... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Correlations Between the EGFR Mutation Status and Clinicopathological Features of Clinical Stage I L... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The initial set of trials will focus on different questions: (1) Exceptional Responders Initiative-w... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Activation of EGFR signaling pathway leads to prostate cancer bone metastasis; however, therapies ta... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Yes-associated protein (YAP) has been reported to be associated with the prognosis of various cancer... | DisGeNET | Detail |
The crosstalk between PAFR and EGFR suggests a potentially important signaling linkage between infla... | DisGeNET | Detail |
We found that ErbB-1 was localized predominantly in the nucleus of ovarian cancer cells examined, co... | DisGeNET | Detail |
Of the two postulated miR-7 target genes we examined, BCL2, but not EGFR, seems to be a possible miR... | DisGeNET | Detail |
Both epidermal growth factor receptor (EGFR) and fibroblast growth factor receptor 1 (FGFR1) are ove... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Gene regulatory biomarker identification for skin toxicities induced by EGFR inhibitor treatment. | DisGeNET | Detail |
NA | DisGeNET | Detail |
HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlo... | DisGeNET | Detail |
If ultimately shown to reduce the risk of oral cancer, chemoprevention with EGFR inhibitors may sign... | DisGeNET | Detail |
Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response r... | DisGeNET | Detail |
Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma ce... | DisGeNET | Detail |
Targeted therapy against the epidermal growth factor receptor (EGFR) only variably represents a ther... | DisGeNET | Detail |
The tumor antigen (TA)-targeted monoclonal antibodies (mAb) cetuximab and panitumumab target the hum... | DisGeNET | Detail |
These findings underscore the importance of ADAM17 and suggest that D1(A12) might be an effective ta... | DisGeNET | Detail |
The expression and subcellular localization of β-catenin and EGFR activation were also studied in HP... | DisGeNET | Detail |
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor and is overe... | DisGeNET | Detail |
We investigated the effects of cetuximab (EGFR antibody) and IMC-A12 (IGF-1R antibody) on the respon... | DisGeNET | Detail |
Identification of epidermal growth factor receptor (EGFR) genetic variants that modify risk for head... | DisGeNET | Detail |
We show that upon EGF stimulation, EGFR and RhoC were strongly activated in HNSCC. | DisGeNET | Detail |
Further, large scale automated alignment of sequencing are unlikely to identify EGFRvIII and an assa... | DisGeNET | Detail |
However, many patients with HNSCC respond poorly to the EGFR inhibitors (EGFRI) cetuximab and erloti... | DisGeNET | Detail |
Epidermal growth factor receptor (EGFR) and its downstream elements are overexpressed in most cases ... | DisGeNET | Detail |
Cetuximab is the only approved molecular targeting agent for HNSCC and despite ubiquitous expression... | DisGeNET | Detail |
To date, cetuximab is the only FDA-approved anti-epidermal growth factor receptor therapy for the tr... | DisGeNET | Detail |
Breast cancer 1 (BRCA1)-associated breast cancers are mostly basal-like high-grade ductal carcinomas... | DisGeNET | Detail |
Short telomere lengths have been previously associated with triple-negative and human epidermal grow... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
EGFR (exons 18-21) and Kirsten RNA-associated rat sarcoma 2 virus (exon 2) mutations were determined... | DisGeNET | Detail |
Compared with patients with ALK(-) lung adenocarcinomas (33 patients; 12 with epidermal growth facto... | DisGeNET | Detail |
De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR muta... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Thus, the association between diverse activating mutations in EGFR and other subclonal mutations wit... | DisGeNET | Detail |
Surprisingly, the authors identify convergent evolution of multiple, mutually exclusive, independent... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The aim of this study was to compare colorectal adenocarcinoma with mucinous component, ordinary ade... | DisGeNET | Detail |
NA | DisGeNET | Detail |
EGFR(epidermal growth factor receptor) mutations and ALK(anaplastic lymphoma kinase) rearrangement a... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
All of the cases of six cerebellar GBMs were p53‑positive and EGFR‑negative, as detected by immunost... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Ovarian serous carcinomas (n=112) and solid metastases (n=63; total=175) were analyzed for mRNA expr... | DisGeNET | Detail |
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in ... | DisGeNET | Detail |
Previous studies have demonstrated that combinatorial treatment of PDAC xenografts with the mitogen-... | DisGeNET | Detail |
Inactivating Sox9 expression in mice confirmed its role in PDAC initiation; it demonstrated that Sox... | DisGeNET | Detail |
These results suggest that dysregulation of ubiquitination is a key mechanism of EGFR hyperactivatio... | DisGeNET | Detail |
(i) hERG1 was expressed at high levels in 59% of primary PDAC; (ii) hERG1 blockade decreased PDAC ce... | DisGeNET | Detail |
Proteomic analysis evidenced that MEK1 inhibition was accompanied by a sustained activation of the P... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We proposed to investigate the distribution of concurrent oncogene mutations in stage Ib lung adenoc... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
EGFR mutations were previously found in patients suffering from peritoneal mesothelioma but have not... | DisGeNET | Detail |
Next, the identification of less EGFR mutations in the EGFR gene of the pleural mesothelioma an up t... | DisGeNET | Detail |
Lung and renal cancer, two areas in which huge progress has been made in the last decade, will be us... | DisGeNET | Detail |
Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGF... | DisGeNET | Detail |
NA | DisGeNET | Detail |
In addition to the well-known characteristics of patients carrying EGFR mutations (female, adenocarc... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
For example, CDH3 was significantly up-regulated in the stromals of both breast and prostate tumors,... | DisGeNET | Detail |
Positive Interplay Between CD3+ T-lymphocytes and Concurrent COX-2/EGFR Expression in Canine Maligna... | DisGeNET | Detail |
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breas... | DisGeNET | Detail |
Impact of epidermal growth factor receptor and transforming growth factor-α on hepatitis C virus-ind... | DisGeNET | Detail |
Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigene... | DisGeNET | Detail |
Correlation between EGFR amplification and the expression of microRNA-200c in primary glioblastoma m... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Basal cell carcinoma of the prostate is an aggressive tumor with frequent loss of PTEN expression an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
In this study, the role of EGFR in tumor angiogenesis was examined in H292 NSCLC cells under the pre... | DisGeNET | Detail |
EGFR is involved in the tumor angiogenesis of HNSCC via the HIF-1α and Notch1 pathways. | DisGeNET | Detail |
Association of EGFR expression level and cetuximab activity in patient-derived xenograft models of h... | DisGeNET | Detail |
Moreover, combined therapeutic inhibition of EGFR and c-Kit may abrogate this acquired mechanism of ... | DisGeNET | Detail |
In vivo studies using mouse xenograft models of CRC showed that Erbin promotes tumour growth, and th... | DisGeNET | Detail |
We engineered the human NSCLC cell line PC-9 (MET-positive cells harboring an exon 19 deletion of EG... | DisGeNET | Detail |
Breast cancer 1 (BRCA1)-associated breast cancers are mostly basal-like high-grade ductal carcinomas... | DisGeNET | Detail |
Short telomere lengths have been previously associated with triple-negative and human epidermal grow... | DisGeNET | Detail |
Approaches used in this investigation include: bioluminescence imaging (BLI) for monitoring intracra... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Interestingly, the extent of these SHP2 signaling regulatory functions is diminished in glioblastoma... | DisGeNET | Detail |
These findings may explain reports on the common occurrence of mutant EGFR (EGFRvIII) and EGFR expan... | DisGeNET | Detail |
Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involve... | DisGeNET | Detail |
Although EGFR phosphorylation and STAT3 activation are essential for the maintenance of GBM cancer s... | DisGeNET | Detail |
Tf-NP-miR-1 treatment on GBM spheres significantly inhibited migration of GBM spheres by 30-50% with... | DisGeNET | Detail |
Together with our previous findings, these data suggest that GRh2 may suppress GBM growth through it... | DisGeNET | Detail |
EGFR gene amplification also represents a signature of genetic abnormality in GBM. | DisGeNET | Detail |
Elevated expression of Notch-1 and EGFR induced apoptosis in glioblastoma multiforme patients. | DisGeNET | Detail |
A common characteristic of glioblastoma multiforme histology is EGFR amplification, which affects si... | DisGeNET | Detail |
Endogenous expressions of EGFR in various GBM cells were determined by western blotting. | DisGeNET | Detail |
By immunohistochemistry EGFR and TGF-α were overexpressed in HCC and cirrhotic cases compared to CHC... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Erlotinib combined with pemetrexed/cisplatin may be effective in the treatment of LM in EGFR mutatio... | DisGeNET | Detail |
It represents a potential therapeutic option against LM after failure of standard-dose EGFR-TKIs, es... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
EGFR mutations may play an important role in the formation of MPE. | DisGeNET | Detail |
SERS measurement based on sea-urchin-like AuNC was an efficient method for EGFR mutation detection i... | DisGeNET | Detail |
Metastatic RET-rearranged lung adenocarcinoma patients with MPE might have favorable survival compar... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
These new findings about endometrial cancer suggest a potential for targeted therapy with lapatinib,... | DisGeNET | Detail |
The protein expression of PCNA and EGFR was significantly higher in high-grade than low-grade glioma... | DisGeNET | Detail |
NA | DisGeNET | Detail |
This study suggests that γ-H2AX is associated with angiogenesis of HCC and γ-H2AX or a combination o... | DisGeNET | Detail |
B3GNT2, a polylactosamine synthase, regulates glycosylation of EGFR in H7721 human hepatocellular ca... | DisGeNET | Detail |
UNC50 prompts G1/S transition and proliferation in HCC by regulation of epidermal growth factor rece... | DisGeNET | Detail |
These results suggested that ECHS1 may promote cell proliferation in HCC in an EGFR-dependent manner... | DisGeNET | Detail |
Overexpression of EGFR in HCC patients can be promising in selecting those who can get benefit from ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Expression levels of p16, β-catenin, and epidermal growth factor receptor (EGFR) were examined in OP... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Although KRAS mutation has a predictive role in stage IV colorectal cancer (CRC) patients treated wi... | DisGeNET | Detail |
We assume that the LCNEC originated from the adenocarcinoma based on the fact that the patient was a... | DisGeNET | Detail |
NA | DisGeNET | Detail |
Despite the efficacy and superiority of EGFR TKIs over chemotherapy as first-line therapy, all patie... | DisGeNET | Detail |
Triple-negative breast cancer (TNBC) is a distinct breast cancer subtype defined by the absence of e... | DisGeNET | Detail |
Mutations in exons 19 and 21 of EGFR are commonly found to be associated with non small cell lung ca... | DisGeNET | Detail |
In aggressive, triple-negative, basal-like breast cancers, most tumors display increased MEK and ERK... | DisGeNET | Detail |
Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negati... | DisGeNET | Detail |
When TNBCs were divided into basal (cytokeratin 5/6 (CK5/6)+ and/or epidermal growth factor receptor... | DisGeNET | Detail |
We used cell line models of EGFR-positive/PTEN null TNBC to elucidate the signaling networks that dr... | DisGeNET | Detail |
Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibi... | DisGeNET | Detail |
The further determination of how the NHERF1‑EGFR interaction is regulated may improve our understand... | DisGeNET | Detail |
The distinct expression of AR and EGFR and the prevalence of BRCA1 mutation indicated that AR, EGFR,... | DisGeNET | Detail |
Triple negative breast cancer (TNBC) is a distinct breast cancer subtype, which is defined by the ab... | DisGeNET | Detail |
Here, we describe how PEA-15 expression affects the dephosphorylation of epidermal growth factor rec... | DisGeNET | Detail |
Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer. | DisGeNET | Detail |
Signaling via epidermal growth factor receptor (EGFR) and Src kinase pathways promote triple-negativ... | DisGeNET | Detail |
The expression of p53 was higher in luminal B, HER2-enriched, and triple-negative breast cancers, an... | DisGeNET | Detail |
EGFR is one of the best-validated driver genes for TNBC. | DisGeNET | Detail |
Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Inhibition of USP8 or EGFR is promising for treating USP8-mutated corticotrophin adenoma. | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Amphiregulin is a member of the family of epidermal growth factor receptor (EGFR) agonists with cell... | DisGeNET | Detail |
These findings provide important information on the mechanisms involved in the progression of astroc... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a ... | DisGeNET | Detail |
Dual regulation of receptor tyrosine kinase genes EGFR and c-Met by the tumor-suppressive microRNA-2... | DisGeNET | Detail |
The epidermal growth factor receptor (EGFR) family is reportedly overexpressed in bladder cancer, an... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
The mechanisms that drive therapeutic resistance to EGFR inhibitors in brain tumours are not well de... | DisGeNET | Detail |
Here, human brain tumor-initiating cell (BTIC) lines with different combinations of endogenous EGFR ... | DisGeNET | Detail |
Optical imaging of targeted β-galactosidase in brain tumors to detect EGFR levels. | DisGeNET | Detail |
The naturally secreted and O-GlcNAcylated MIF binds to EGFR, thereby inhibiting the binding of EGF t... | DisGeNET | Detail |
A new class of protein cancer biomarker candidates: differentially expressed splice variants of ERBB... | DisGeNET | Detail |
Complete pharmacologic EGFR/HER2 inhibition is required to reverse Src-dependent resistance to lapat... | DisGeNET | Detail |
This is a revised case report of a 52 year old Caucasian female with Li-Fraumeni syndrome with a rar... | DisGeNET | Detail |
We suggest that TJE is a new potential reagent for EGFR-targeted therapy and anti-abnormal metastasi... | DisGeNET | Detail |
The targeting of the hormone receptor, HER2 and EGFR1 in breast cancer will be reviewed in associati... | DisGeNET | Detail |
The epidermal growth factor receptor (EGFR) is a member of the ErbB family that can promote the migr... | DisGeNET | Detail |
Here, we report a proof-of-concept experiment demonstrating that small peptides interfering with the... | DisGeNET | Detail |
Our results showed that CD44 expression was significantly increased by epidermal growth factor recep... | DisGeNET | Detail |
Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-posi... | DisGeNET | Detail |
In both the primary cancers and the metastases, Claudin-4 was most frequently expressed, followed by... | DisGeNET | Detail |
BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells ... | DisGeNET | Detail |
Because mutations within HER1/EGFR are predictive of response to tyrosine kinase inhibitors (TKI) in... | DisGeNET | Detail |
Oncogenic signaling in amphiregulin and EGFR-expressing PTEN-null human breast cancer. | DisGeNET | Detail |
Coexpression of EGFR and HER2 has been associated with poor disease outcome, high rates of metastasi... | DisGeNET | Detail |
While ERBB1, ERBB2 and ERBB3 are often overexpressed or activated in breast cancer, and are oncogeni... | DisGeNET | Detail |
We propose that miR-7 regulated pathways, including EGFR and Src kinase, represent targets for the t... | DisGeNET | Detail |
Estrogen-responsive genes most significantly influenced by cohesin were enriched in pathways associa... | DisGeNET | Detail |
This study identifies mutant p53 as an essential player in ErbB2 and EGFR-mediated mammary tumorigen... | DisGeNET | Detail |
TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer. | DisGeNET | Detail |
Lapatinib, a dual tyrosine kinase inhibitor that interrupts the epidermal growth factor receptor (EG... | DisGeNET | Detail |
Amplified HER2, which encodes a member of the epidermal growth factor receptor (EGFR) family, is a t... | DisGeNET | Detail |
Further understanding of the paradoxical function of EGFR between primary and metastatic tumors will... | DisGeNET | Detail |
Loss of catalytically functional PTPN14 increased the secretion of growth factors and cytokines, suc... | DisGeNET | Detail |
More and more evidences demonstrate that androgen receptor (AR), epidermal growth factor receptor (E... | DisGeNET | Detail |
Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybri... | DisGeNET | Detail |
A benzimidazole derivative exhibiting antitumor activity blocks EGFR and HER2 activity and upregulat... | DisGeNET | Detail |
To identify a prognostic signature for breast cancer, we performed DNA methylation profiling and ide... | DisGeNET | Detail |
Kindlin-2 interacts with and stabilizes EGFR and is required for EGF-induced breast cancer cell migr... | DisGeNET | Detail |
Upregulation of HER3 has been found to be a major mechanism underlying drug resistance to EGFR and H... | DisGeNET | Detail |
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human ep... | DisGeNET | Detail |
Correlation between p53 and epidermal growth factor receptor expression in breast cancer classificat... | DisGeNET | Detail |
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Ac... | DisGeNET | Detail |
Requirement of ERα and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK ... | DisGeNET | Detail |
The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal grow... | DisGeNET | Detail |
Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Here we show a clear correlation between the efficacy of anti-EGFR inhibitors with their ability to ... | DisGeNET | Detail |
These results indicate that ERBB3 is a potential target for EGFR- and ERBB2-resistant colon cancer t... | DisGeNET | Detail |
Importantly, hyperactivation of SRC/EGFR signaling triggered by loss of PTPRO leads to high resistan... | DisGeNET | Detail |
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells. | DisGeNET | Detail |
KRAS mutations also induce anti-EGFR antibody resistance in adenocarcinoma such as colon cancer. | DisGeNET | Detail |
Mutations at the K-RAS locus in colon cancer cells are frequently associated with lack of responsive... | DisGeNET | Detail |
In contrast, forced expression of MITF in melanoma and colon cancer cells inhibited EGFR and conferr... | DisGeNET | Detail |
These new findings about endometrial cancer suggest a potential for targeted therapy with lapatinib,... | DisGeNET | Detail |
Higher expression of the EGFR cascade in cannabis smokers revealed that cannabis smoking may be a ma... | DisGeNET | Detail |
Molecular Characterization of KRAS, BRAF, and EGFR Genes in Cases with Prostatic Adenocarcinoma; Rep... | DisGeNET | Detail |
EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based ... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
We assume that the LCNEC originated from the adenocarcinoma based on the fact that the patient was a... | DisGeNET | Detail |
A significantly higher incidence of EGFR mutations was observed in bronchioloalveolar carcinomas (28... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
A single-institute cohort study in Taiwan was performed to determine the mutations of epidermal grow... | DisGeNET | Detail |
The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pu... | DisGeNET | Detail |
The aim of this study was to compare colorectal adenocarcinoma with mucinous component, ordinary ade... | DisGeNET | Detail |
NA | DisGeNET | Detail |
NA | DisGeNET | Detail |
Overlapped Transcript Coordinates
Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
---|
Overlapped Transcript
Gene | Transcript ID | Chromosome | Start | Stop | Links |
---|
- Gene
- -
- dbSNP
- rs17337023 dbSNP
- Genome
- hg19
- Position
- chr7:55,086,710-55,279,321
- Variant Type
- snv
- Variant (CIViC) (CIViC Variant)
- 3' UTR MUTATION
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/253
- Variant (CIViC) (CIViC Variant)
- S752_I759delSPKANKEI
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/891
- Variant (CIViC) (CIViC Variant)
- V851I
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/1466
- Variant (CIViC) (CIViC Variant)
- V774_C775insHV
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/1567
- Variant (CIViC) (CIViC Variant)
- D770_N771insNPG
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/1569
- Variant (CIViC) (CIViC Variant)
- D770_N771insGY
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/1666
- Variant (CIViC) (CIViC Variant)
- P772_H773insYNP
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/1667
- Variant (CIViC) (CIViC Variant)
- P772_V774insPHV
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/1668
- Variant (CIViC) (CIViC Variant)
- Ex19 del L858R
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/1854
- Variant (CIViC) (CIViC Variant)
- RARE EX 18-21 MUT
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/1863
- Summary (CIViC Variant)
- Rare exon 18-21 mutations in EGFR consist of all EGFR mutations excluding sensitizing L858R substitutions and exon 19 deletions, as well as resistance mutation T790M.
Genome browser